Movatterモバイル変換


[0]ホーム

URL:


EP3192491B1 - Composition comprising polyglycerol esters and hydroxy-alkyl modified guar - Google Patents

Composition comprising polyglycerol esters and hydroxy-alkyl modified guar
Download PDF

Info

Publication number
EP3192491B1
EP3192491B1EP16151443.5AEP16151443AEP3192491B1EP 3192491 B1EP3192491 B1EP 3192491B1EP 16151443 AEP16151443 AEP 16151443AEP 3192491 B1EP3192491 B1EP 3192491B1
Authority
EP
European Patent Office
Prior art keywords
mol
acid
carboxylic acid
aluminum
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP16151443.5A
Other languages
German (de)
French (fr)
Other versions
EP3192491A1 (en
Inventor
Achim Friedrich
Jürgen Meyer
Frank Unger
Verena Dahl
Jan Marian Von Hof
Oliver Springer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evonik Operations GmbH
Original Assignee
Evonik Operations GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Operations GmbHfiledCriticalEvonik Operations GmbH
Priority to EP16151443.5ApriorityCriticalpatent/EP3192491B1/en
Priority to US15/380,137prioritypatent/US20170202770A1/en
Priority to BR102017000660-3Aprioritypatent/BR102017000660B1/en
Priority to CN201710032429.2Aprioritypatent/CN107028795B/en
Publication of EP3192491A1publicationCriticalpatent/EP3192491A1/en
Application grantedgrantedCritical
Publication of EP3192491B1publicationCriticalpatent/EP3192491B1/en
Activelegal-statusCriticalCurrent
Anticipated expirationlegal-statusCritical

Links

Images

Classifications

Definitions

Landscapes

Description

Translated fromGerman
Gebiet der ErfindungField of the Invention

Gegenstand der Erfindung sind Zusammensetzungen enthaltend Polyglycerinester und langkettig hydroxy-alkylmodifiziertes Guar.The invention relates to compositions containing polyglycerol esters and long-chain hydroxy-alkyl-modified guar.

Stand der TechnikState of the art

WO2013092186 offenbart eine schweißhemmende Zusammensetzung in Form einer Öl-in-Wasser-Emulsion, die keine Mikroemulsion ist, enthaltend

  1. a) mindestens ein schweißhemmendes Aluminiumsalz in einer Gesamtmenge von 2 - 40 Gew%, wobei sich die Gew.-%-Angaben auf das Gesamtgewicht der kristallwasserfreien und ligandenfreien Aktivsubstanz (USP) in dem Mittel beziehen, und zusätzlich dazu
  2. b) in einer Gesamtmenge von 0, 1 - 2 Gew.-% mindestens eine oberflächenaktive Verbindung mit einem HLB-Wert im Bereich von 9 bis 15, ausgewählt aus den Partialestern eines Polyglycerins, das 3, 4 oder 5 Glycerin-Einheiten umfasst, mit einer linearen oder verzweigten, gesättigten oder ungesättigten Carbonsäure mit 8 bis 22 C-Atomen und mit einer organischen Genusssäure,
    und zusätzlich dazu
  3. c) in einer Gesamtmenge von 0,1 - 2,0 Gew.-% mindestens ein bestimmtes N-Acyl-L-glutaminsäure-Natriumsalz.
WO2013092186 discloses an antiperspirant composition in the form of an oil-in-water emulsion that is not a microemulsion
  1. a) at least one antiperspirant aluminum salt in a total amount of 2 - 40% by weight, the% by weight data relating to the total weight of the crystal water-free and ligand-free active substance (USP) in the composition, and in addition to this
  2. b) in a total amount of 0.1-2% by weight, at least one surface-active compound with an HLB value in the range from 9 to 15, selected from the partial esters of a polyglycerol which comprises 3, 4 or 5 glycerol units a linear or branched, saturated or unsaturated carboxylic acid with 8 to 22 carbon atoms and with an organic edible acid,
    and in addition to that
  3. c) in a total amount of 0.1 - 2.0 wt .-% at least one specific N-acyl-L-glutamic acid sodium salt.

WO2015132053 offenbart Deodorant Formulierung enthaltend Ester eines Polyglycerins mit Stearinsäure, Palmitinsäure und Caprylsäure, sowie Hydroxyethyl Cellulose. Aufgabe der Erfindung war es, Zusammensetzungen bereitzustellen, die eine niedrigviskose und stabile Formulierung von emulsionsbelastenden Inhaltsstoffen, wie beispielsweise AP/Deo-Wirkstoffen, ermöglichen. WO2015132053 discloses a deodorant formulation comprising esters of a polyglycerol with stearic acid, palmitic acid and caprylic acid, and also hydroxyethyl cellulose. The object of the invention was to provide compositions which enable a low-viscosity and stable formulation of emulsion-stressing ingredients, such as AP / deodorant active ingredients.

Beschreibung der ErfindungDescription of the invention

Überraschenderweise wurde gefunden, dass die im Folgenden beschriebenen Zusammensetzungen die der Erfindung gestellte Aufgabe zu lösen vermögen.Surprisingly, it was found that the compositions described below are able to achieve the object of the invention.

Gegenstand der vorliegenden Erfindung sind daher Zusammensetzungen enthaltend bestimmte Polyglycerinester und hydroxy-alkylmodifiziertes Guar.The present invention therefore relates to compositions comprising certain polyglycerol esters and hydroxyalkyl-modified guar.

Ein Vorteil der vorliegenden Erfindung besteht darin, dass der in den erfindungsgemäßen Zusammensetzungen enthaltene Polyglycerinester vollkommen auf nachwachsenden Rohstoffen basiert.An advantage of the present invention is that the polyglycerol ester contained in the compositions according to the invention is based entirely on renewable raw materials.

Noch ein Vorteil der vorliegenden Erfindung ist es, dass die erfindungsgemäße Zusammensetzung sich zur Formulierung von O/W Emulsionen (Cremes, Lotionen) mit hervorragender Lagerstabilität eignet.Another advantage of the present invention is that the composition according to the invention is suitable for the formulation of O / W emulsions (creams, lotions) with excellent storage stability.

Ein weiterer Vorteil der vorliegenden Erfindung ist es, dass die erfindungsgemäße Zusammensetzung sich zur Formulierung PEG-freier Emulsionen, insbesondere dünnflüssiger PEG-freier Emulsionen eignet.Another advantage of the present invention is that the composition according to the invention is suitable for the formulation of PEG-free emulsions, in particular low-viscosity PEG-free emulsions.

Ein weiterer Vorteil der vorliegenden Erfindung ist es, dass die erfindungsgemäße Zusammensetzung sich zur Formulierung PEG-freier AP/Deo oder Deo-Emulsionen, insbesondere Roll-on-Emulsionen eignet.Another advantage of the present invention is that the composition according to the invention is suitable for the formulation of PEG-free AP / deodorant or deodorant emulsions, in particular roll-on emulsions.

Ein weiterer Vorteil der vorliegenden Erfindung ist es, dass die erfindungsgemäße Zusammensetzung sich zur Formulierung von Emulsionen eignet, welche eine Fließgrenze aufweisen.Another advantage of the present invention is that the composition according to the invention is suitable for the formulation of emulsions which have a yield point.

Emulsionen und Formulierungen enthaltend solchen Emulgator auf Basis der erfindungsgemäßen Zusammensetzung weisen überdies ein gutes Hautgefühl auf. Vorteilhafterweise benötigen Emulsionen und Formulierungen enthaltend die erfindungsgemäße Zusammensetzung keine parabenhaltigen Konservierungsmittel. Ein weiterer Vorteil der vorliegenden Erfindung ist es, dass die erfindungsgemäße Zusammensetzung sich zur Formulierung von Emulsionen ohne polyacrylat-basierte Verdicker eignet.Emulsions and formulations containing such an emulsifier based on the composition according to the invention also have a good feeling on the skin. Emulsions and formulations containing the composition according to the invention advantageously do not require any preservatives containing parabens. A further advantage of the present invention is that the composition according to the invention is suitable for the formulation of emulsions without polyacrylate-based thickeners.

Ein weiterer Vorteil der vorliegenden Erfindung ist es, dass die erfindungsgemäße Zusammensetzung aufgrund ihrer Konsistenz gut handhabbar ist.Another advantage of the present invention is that the composition according to the invention is easy to handle due to its consistency.

Ein weiterer Vorteil der vorliegenden Erfindung ist es, dass die erfindungsgemäße Zusammensetzung in Formulierungen ein leichtes Hautgefühl erzeugt.Another advantage of the present invention is that the composition according to the invention produces a light skin feeling in formulations.

Ein weiterer Vorteil der vorliegenden Erfindung ist es, dass die Verwendung der erfindungsgemäßen Zusammensetzung den Formulierungen feuchtigkeitsspendende Eigenschaften verleiht.Another advantage of the present invention is that the use of the composition according to the invention imparts moisturizing properties to the formulations.

Beansprucht wird daher eine Zusammensetzung enthaltend

  1. A) Polyglycerinester, der nach seiner vollständiger Hydrolyse
    1. a) mindestens eine Carbonsäure mit 6 bis 14, bevorzugt 8 bis 12, Kohlenstoffatomen
    2. b) mindestens eine Carbonsäure mit 16 bis 20, bevorzugt 18 bis 20, Kohlenstoffatomen
    3. c) mindestens eine Carbonsäure mit 22 bis 28, bevorzugt 22 bis 24, Kohlenstoffatomen freisetzt und
      der nach seiner vollständiger Hydrolyse ein Polyglycerin freisetzt, das einen mittleren Polymerisationsgrad von 3,0 bis 5,0, bevorzugt von 3,3 bis 4,7, besonders bevorzugt von 3,6 bis 4,5, aufweist,
      und
  2. B) mindestens ein hydroxy-alkylmodifziertes Guar,
    dadurch gekennzeichnet, dass das hydroxy-alkylmodifzierte Guar mit HydroxyAlkylgruppen mit 12 bis 26, bevorzugt 16 bis 24, besonders bevorzugt 18 bis 22, Kohlenstoffatomen modifiziert ist.
A composition containing is therefore claimed
  1. A) Polyglycerol ester, which after its complete hydrolysis
    1. a) at least one carboxylic acid having 6 to 14, preferably 8 to 12, carbon atoms
    2. b) at least one carboxylic acid having 16 to 20, preferably 18 to 20, carbon atoms
    3. c) releases at least one carboxylic acid with 22 to 28, preferably 22 to 24, carbon atoms and
      which after its complete hydrolysis releases a polyglycerol which has an average degree of polymerization from 3.0 to 5.0, preferably from 3.3 to 4.7, particularly preferably from 3.6 to 4.5,
      and
  2. B) at least one hydroxy-alkyl-modified guar,
    characterized in that the hydroxy-alkyl-modified guar is modified with hydroxyalkyl groups having 12 to 26, preferably 16 to 24, particularly preferably 18 to 22, carbon atoms.

Unter dem Begriff "Polyglycerin" im Sinne der vorliegenden Erfindung ist ein Polyglycerin zu verstehen, welches Glycerin enthält. Somit ist zur Berechnung von Mengen, Massen und dergleichen der Glycerinanteil mit zu berücksichtigen. Polyglycerine im Sinne der vorliegenden Erfindung sind somit Mischungen von Glycerin mit mindestens einem Glycerin-Oligomer. Unter Glycerin-Oligomeren sind jeweils alle entsprechenden Strukturen, z.B. also lineare und zyklische Verbindungen zu verstehen.The term “polyglycerin” in the context of the present invention is to be understood as meaning a polyglycerin which contains glycerin. Thus, the glycerol content must also be taken into account when calculating amounts, masses and the like. For the purposes of the present invention, polyglycerols are therefore mixtures of glycerol with at least one glycerol oligomer. Glycerol oligomers include all corresponding structures, e.g. to understand linear and cyclic connections.

Analoges gilt für den Begriff "Polyglycerinester" im Zusammenhang mit der vorliegenden Erfindung.The same applies to the term "polyglycerol ester" in connection with the present invention.

Das angegebene Zahlenmittel der Säurereste bezieht sich bei mehr als einer der Carbonsäure a), b) oder c) jeweils auf die akkumulierte Summe aller Carbonsäuren a), b) oder c).In the case of more than one of the carboxylic acids a), b) or c), the number average of the acid residues relates in each case to the accumulated sum of all carboxylic acids a), b) or c).

Der mittlere Polymerisationsgrad des PolyglycerinsN wird über dessen Hydroxylzahl OHV, in mg KOH/g) gemäß folgender Formel berechnet:N=11220018OHV74OHV56100

Figure imgb0001
The average degree of polymerization of the polyglycerolN is calculated via its hydroxyl number OHV, in mg KOH / g) according to the following formula: N = 112200 - 18 OHV 74 OHV - 56100
Figure imgb0001

Geeignete Bestimmungsmethoden zur Ermittlung der Hydroxylzahl sind insbesondere solche gemäß DGF C-V 17 a (53), Ph. Eur. 2.5.3 Method A und DIN 53240.Suitable determination methods for determining the hydroxyl number are in particular those according to DGF C-V 17 a (53), Ph. Eur. 2.5.3 Method A and DIN 53240.

Alle angegebenen Prozent (%) sind, wenn nicht anders angegeben, Massenprozent.Unless stated otherwise, all percentages (%) are percentages by mass.

Es werden erfindungsgemäß Zusammensetzungen bevorzugt, bei denen das nachvollständiger Hydrolyse des Polyglycerinesters freigesetzte Polyglycerin ein Massenverhältnis von Glycerin zu Diglycerin von größer 1, bevorzugt größer 1,2, besonders bevorzugt größer 1,4 aufweist.Compositions according to the invention are preferred in which the complete hydrolysis of the polyglycerol ester released polyglycerol has a mass ratio of glycerol to diglycerol of greater than 1, preferably greater than 1.2, particularly preferably greater than 1.4.

Es werden erfindungsgemäß Zusammensetzungen besonders bevorzugt, bei denen das nach vollständiger Hydrolyse des Polyglycerinesters freigesetzte Polyglycerin 5 Gew.-% bis 30 Gew.-%, bevorzugt 7 Gew.-% bis 25 Gew.-%, besonders bevorzugt
10 Gew.-% bis 22 Gew.-%, mono-Glycerin,
1 Gew.-% bis 25 Gew.-%, bevorzugt 3 Gew.-% bis 18 Gew.-%, besonders bevorzugt 5 Gew.-% bis 15 Gew.-%, Diglycerine,
1 Gew.-% bis 25 Gew.-%, bevorzugt 1 Gew.-% bis 20 Gew.-%, besonders bevorzugt 3 Gew.-% bis 17 Gew.-%, Triglycerine und
1 Gew.-% bis 20 Gew.-%, bevorzugt 2 Gew.-% bis 15 Gew.-%, besonders bevorzugt 4 Gew.-% bis 10 Gew.-%, Tetraglycerine
enthält, wobei sich die Gewichtsprozente auf das gesamte Polyglycerin beziehen.
Compositions are particularly preferred according to the invention in which the polyglycerol released after complete hydrolysis of the polyglycerol ester is particularly preferably 5% by weight to 30% by weight, preferably 7% by weight to 25% by weight
10% by weight to 22% by weight, mono-glycerol,
1% by weight to 25% by weight, preferably 3% by weight to 18% by weight, particularly preferably 5% by weight to 15% by weight, diglycerols,
1% by weight to 25% by weight, preferably 1% by weight to 20% by weight, particularly preferably 3% by weight to 17% by weight, triglycerols and
1% by weight to 20% by weight, preferably 2% by weight to 15% by weight, particularly preferably 4% by weight to 10% by weight, tetraglycerols
contains, the weight percentages refer to the total polyglycerol.

In diesem Zusammenhang weist das freigesetzte Polyglycerin bevorzugt
≥70 Gew.-%, bevorzugt ≥75 Gew.-%, besonders bevorzugt ≥80 Gew.-%, Polyglycerine mit einem Polymerisationsgrad von ≥2,
≥60 Gew.-%, bevorzugt ≥65 Gew.-%, besonders bevorzugt ≥70 Gew.-%, Polyglycerine mit einem Polymerisationsgrad von ≥3,
≥50 Gew.-%, bevorzugt ≥55 Gew.-%, besonders bevorzugt ≥60 Gew.-%, Polyglycerine mit einem Polymerisationsgrad von ≥4 und
≥40 Gew.-%, bevorzugt ≥45 Gew.-%, besonders bevorzugt ≥50 Gew.-%, Polyglycerine mit einem Polymerisationsgrad von ≥5
auf, wobei sich die Gewichtsprozent auf das gesamte Polyglycerin beziehen.
In this connection, the released polyglycerol is preferred
≥70% by weight, preferably ≥75% by weight, particularly preferably ≥80% by weight, polyglycerols with a degree of polymerization of ≥2,
≥60% by weight, preferably ≥65% by weight, particularly preferably ≥70% by weight, polyglycerols with a degree of polymerization of ≥3,
≥50% by weight, preferably ≥55% by weight, particularly preferably ≥60% by weight, polyglycerols with a degree of polymerization of ≥4 and
≥40% by weight, preferably ≥45% by weight, particularly preferably ≥50% by weight, polyglycerols with a degree of polymerization of ≥5
on, the weight percent based on the total polyglycerol.

Der Massenanteil von Glycerin, Diglycerin, Triglycerin, Tetraglycerin sowie der Fettsäuren lässt sich im Rahmen der vorliegenden Erfindung durch zwei GC-Methoden bestimmen; diese Methoden beinhalten die alkalische Hydrolyse des erfindungsgemäßen Polyglycerinesters, Trennung des Polyglycerins von den freigesetzten Säuren und Analyse der Fettsäuren sowie der Glycerin-Oligomere (lineare und zyklische).The mass fraction of glycerin, diglycerin, triglycerin, tetraglycerin and the fatty acids can be determined in the context of the present invention by two GC methods; these methods include the alkaline hydrolysis of the polyglycerol ester according to the invention, separation of the polyglycerol from the released acids and analysis of the fatty acids and of the glycerol oligomers (linear and cyclic).

Hierzu werden 0,5 g des erfindungsgemäßen Polyglycerinesters in 25 ml einer ethanolischen 0,5 M KOH Lösung unter Rückfluss für 4 Stunden gekocht. Dann werden 10 ml Wasser zugegeben und der pH mit Schwefelsäure auf pH 2-3 eingestellt. Die entstandenen Carbonsäuren werden durch dreimalige Extraktion mit jeweils einem Volumen (20 ml) Petrolether abgetrennt.For this purpose, 0.5 g of the polyglycerol ester according to the invention is boiled in 25 ml of an ethanolic 0.5 M KOH solution under reflux for 4 hours. Then 10 ml of water are added and the pH is adjusted to pH 2-3 with sulfuric acid. The carboxylic acids formed are separated off by extraction three times, each with a volume (20 ml) of petroleum ether.

Fettsäureanalyse :Fatty acid analysis:

Die vereinigten Extrakte werden durch Evaporation auf ca. 1 ml eingeengt. Geeignete Bestimmungsmethoden zur Ermittlung der Fettsäureverteilung sind insbesondere solche gemäß DGF C VI 11a, DGF C-VI 10 a und GAT - Ringtest 7/99. Ein 0,5 ml Aliquot des wie oben beschriebenen erhaltenen Petroletherextraktes wird in einem Gefäß mit 1 ml einer Mischung von Acetylchlorid: Methanol (1:4) unter Ausschluss von Luftfeuchtigkeit 30 min in der Siedehitze behandelt. Die entstehenden Fettsäuremethylester werden 2 mal mit jeweils 5 ml iso-Octan extrahiert und mittels GC analysiert. Dieses wird in einem Gaschromatograph, welcher mit einem split/splitless Injektor, einer Kapillarsäule und einem Flammenionisationdetektor ausgestattet ist, unter folgenden Bedingungen durchgeführt:Injektor:290 °C, Split 30 mlInjektionsvolumen:1 µlSäule:30 m *0,32 mm HP1 0,25 µmTrägergas:Helium, constant flow, 2 mL/minTemperaturprogramm:80 °C - 300 °C mit 8 °C/min, dann 10 Minuten bei 300 °C konditionieren.Detektor:FID bei 320 °CWasserstoff 35 ml/minLuft 240 ml/minMake Up Gas 12 ml/minThe combined extracts are concentrated to about 1 ml by evaporation. Suitable determination methods for determining the fatty acid distribution are in particular those according to DGF C VI 11a, DGF C-VI 10 a and GAT - ring test 7/99. A 0.5 ml aliquot of the petroleum ether extract obtained as described above is treated in a vessel with 1 ml of a mixture of acetyl chloride: methanol (1: 4) with the exclusion of atmospheric moisture at the boiling point for 30 minutes. The resulting fatty acid methyl esters are extracted twice with 5 ml each of iso-octane and analyzed by GC. This is carried out in a gas chromatograph equipped with a split / splitless injector, a capillary column and a flame ionization detector under the following conditions: injector: 290 ° C, split 30 ml Injection volume: 1 µl Pillar: 30 m * 0.32 mm HP1 0.25 µm Carrier gas: Helium, constant flow, 2 mL / min Temperature program: Condition 80 ° C - 300 ° C at 8 ° C / min, then 10 minutes at 300 ° C. Detector: FID at 320 ° C Hydrogen 35 ml / min Air 240 ml / min Make up gas 12 ml / min

Die Carbonsäuren werden als ihre Methylester nach ihrer Kohlenstoffkettenlänge getrennt und ihr Massenanteil nach einer Methode des internen Standards bestimmt. Hierzu wird das GC System durch Vermessen von Fettsäuremethylester-Mischungen der zu untersuchenden Fettsäuren mit bekannter Zusammensetzung kalibriert. Mit diesem Verfahren wird die Gesamtmasse und die Massenanteile an Carbonsäure(n) erhalten, die über die Verwendung der jeweiligen Molekulargewichte eine Bestimmung der Stoffemenge(n) erlaubt. Aus der Gesamtmasse an Carbonsäure(n) lässt sich außerdem durch Subtraktion die z.B. in 0.5 g Polyglycerinester enthaltene Masse an Polyglycerin bestimmen.
Mittels des Molekulargewichts des Polyglycerins lässt sich daraus die Stoffmenge des Polyglycerins bestimmen.Mp =74·N+18mitMp = Molekulargewicht des Polyglycerins [g/mol]N = Polymerisationsgrad des Polyglycerins (zur Bestimmung des Polymerisationsgrads siehe weiter unten).np=mpMp

Figure imgb0002
mitnp = Stoffmenge des Polyglycerins [mol] in 1 gPolyglycerinestermp = Masse Polyglycerin in 1 g Polyglycerinester [g]Mp = Molekulargewicht des Polyglycerins [g/mol]The carboxylic acids are separated as their methyl esters according to their carbon chain length and their mass fraction is determined using an internal standard method. For this purpose, the GC system is calibrated by measuring fatty acid methyl ester mixtures of the fatty acids to be examined with a known composition. With this method, the total mass and the mass fractions of carboxylic acid (s) are obtained, which allows the amount of substance (s) to be determined by using the respective molecular weights. From the total mass of carboxylic acid (s), the mass of polyglycerol contained, for example, in 0.5 g of polyglycerol ester can also be determined by subtraction.
The amount of substance of the polyglycerol can be determined therefrom by means of the molecular weight of the polyglycerol.Mp = 74 *N +18 With Mp = molecular weight of polyglycerol [g / mol] N = degree of polymerization of the polyglycerol (for determination of the degree of polymerization see below). n p = m p M p
Figure imgb0002
With np = amount of substance of polyglycerol [mol] in 1 g
polyglycerol mp = mass of polyglycerol in 1 g of polyglycerol ester [g] Mp = molecular weight of polyglycerol [g / mol]

Zusammen lassen sich aus diesen Werten die Molverhältnisse von Polyglycerin zu Carbonsäuren bestimmen.Together, the molar ratios of polyglycerol to carboxylic acids can be determined from these values.

Analyse von Glycerin, Diglycerinen, Triglycerinen und Tetraglycerinen:
Der mit Petrolether extrahierte Rückstand wird mit Bariumhydroxid auf pH 7 bis 8 eingestellt. Das ausgefallene Bariumsulfat wird durch Zentrifugation abgetrennt.
Der Überstand wird abgenommen und der Rückstand wird dreimal mit 20 ml Ethanol extrahiert.
Die vereinigten Überstände werden für 30 min bei 80 °C und 50 mbar eingeengt und getrocknet.
Analysis of glycerol, diglycerols, triglycerols and tetraglycerols:
The residue extracted with petroleum ether is adjusted to pH 7 to 8 with barium hydroxide. The precipitated barium sulfate is separated off by centrifugation.
The supernatant is removed and the residue is extracted three times with 20 ml of ethanol.
The combined supernatants are concentrated at 80 ° C. and 50 mbar for 30 min and dried.

Für die Analyse von Glycerin, Diglycerinen, Triglycerinen und Tetraglycerinen mittels GC wird der Rückstand in 2 ml Pyridin:Chloroform (4:1) gelöst. 0,5 ml dieser Lösung werden mit 1 ml MSTFA [N-Methyl-N-(trimethylsilyl) trifluoroacetamide] versetzt. Die Alkohole werden durch Reaktion bei 80°C (30 Minuten) quantitativ in ihre Trimethylsilyether überführt und anschließend mittels GC/FID untersucht.
Dieses wird in einem Gaschromatograph, welcher mit einem split/splitless Injektor, einer Kapillarsäule und einem Flammenionisationdetektor ausgestattet ist, unter folgenden Bedingungen durchgeführt:Injektor:290 °C, Split 30 mlInjektionsvolumen:1 µlSäule:30 m *0,32 mm HP1 0,25 µmTrägergas:Helium, constant flow, 2 mL/minTemperaturprogramm:80 °C - 300 °C mit 4 °C/min, dann 10 Minuten bei 300 °C konditionieren.Detektor:FID bei 310 °CWasserstoff 35 ml/minLuft 240 ml/minMake Up Gas 12 ml/min
For the analysis of glycerol, diglycerols, triglycerols and tetraglycerols by means of GC, the residue is dissolved in 2 ml of pyridine: chloroform (4: 1). 0.5 ml of this solution is mixed with 1 ml of MSTFA [N-methyl-N- (trimethylsilyl) trifluoroacetamide]. The alcohols are converted quantitatively into their trimethylsilyl ether by reaction at 80 ° C. (30 minutes) and then examined by means of GC / FID.
This is carried out in a gas chromatograph equipped with a split / splitless injector, a capillary column and a flame ionization detector under the following conditions: injector: 290 ° C, split 30 ml Injection volume: 1 µl Pillar: 30 m * 0.32 mm HP1 0.25 µm Carrier gas: Helium, constant flow, 2 mL / min Temperature program: Condition 80 ° C - 300 ° C at 4 ° C / min, then 10 minutes at 300 ° C. Detector: FID at 310 ° C Hydrogen 35 ml / min Air 240 ml / min Make up gas 12 ml / min

Glycerin, Diglycerine, Triglycerine und Tetraglycerine werden aufgetrennt und ihr Massenanteil nach einer Methode des internen Standards bestimmt. Hierzu wird das GC System durch Vermessen von Mischungen der zu untersuchenden Glycerine und des internen Standards mit bekannter Zusammensetzung kalibriert.
Aus den Massenanteilen lässt sich das Massenverhältnis von Glycerin zu Diglycerin bestimmen sowie durch Subtraktion von 100% auch der Gehalt an Polyglycerinen mit einem Polymerisationsgrad von 2 und größer (100% minus Massenanteil des Glycerins), der Gehalt an Polyglycerinen mit einem Polymerisationsgrad von 3 und größer (100% minus Massenanteile des Glycerins und der Diglycerine), der Gehalt an Polyglycerinen mit einem Polymerisationsgrad von 4 und größer (100% minus Massenanteile des Glycerins, der Diglycerine und der Triglycerine) und der Gehalt an Polyglycerinen mit einem Polymerisationsgrad von 5 und größer (100% minus Massenanteile des Glycerins, der Diglycerine, der Triglycerine und der Tetraglycerine). Sollte in einem betrachteten Polyglycerin keine nachweisbare Menge an Diglycerin, jedoch Glycerin enthalten sein, so entspricht dies einem Massenverhältnis von Glycerin zu Diglycerin größer 1,4.
Glycerol, diglycerols, triglycerols and tetraglycerols are separated and their mass fraction determined according to an internal standard method. For this purpose, the GC system is calibrated by measuring mixtures of the glycerols to be examined and the internal standard with a known composition.
From the mass fractions, the mass ratio of glycerin to diglycerol can be determined, and by subtracting 100%, the content of polyglycerols with a degree of polymerization of 2 and greater (100% minus mass fraction of glycerol), the content of polyglycerols with a degree of polymerization of 3 and greater (100% minus mass fractions of glycerin and diglycerols), the content of polyglycerols with a degree of polymerization of 4 and greater (100% minus mass fractions of glycerin, diglycerols and triglycerols) and the content of polyglycerols with a degree of polymerization of 5 and greater ( 100% minus mass fractions of glycerol, diglycerols, triglycerols and tetraglycerols). If there is no detectable amount of diglycerin in a polyglycerol under consideration, but glycerol is present, this corresponds to a mass ratio of glycerol to diglycerol greater than 1.4.

Eine erfindungsgemäß bevorzugte Zusammensetzung ist dadurch gekennzeichnet, dass der Polyglycerinester nach seiner vollständiger Hydrolyse im Mittel (Zahlenmittel) pro Mol Polyglycerinester
von 0,01 bis 0,07 Mol, bevorzugt von 0,01 bis 0,50 Mol, besonders bevorzugt von 0,01 bis 0,30 Mol, mindestens einer Carbonsäure a)
von 0,10 bis 1,70 Mol, bevorzugt von 0,30 bis 1,50 Mol, besonders bevorzugt von 0,40 bis 1,40 Mol, mindestens einer Carbonsäure b)
von 0,01 bis 0,80 Mol, bevorzugt von 0,01 bis 0,60 Mol, besonders bevorzugt von 0,05 bis 0,40 Mol, mindestens einer Carbonsäure c)
freisetzt.
Insbesondere ist sie dadurch gekennzeichnet, dass das Molverhältnis der nach vollständiger Hydrolyse des Polyglycerinesters erhaltenen Carbonsäure a) zu Carbonsäure b) zu Carbonsäure c)
0,6 bis 1,4 : 16,5 bis 20,5 : 3,0 bis 4,8, bevorzugt
0,8 bis 1,2 : 17,5 bis 19,5 : 3,5 bis 4,3, besonders bevorzugt
0,9 bis 1,1 : 18,0 bis 19,0 : 3,7 bis 4,1, beträgt.
Zur Bestimmung der Molverhältnisse lässt sich als Methode die oben beschriebene Methode einsetzen.
Es ist erfindungsgemäß bevorzugt, dass die Carbonsäuren a), b) und c) ausgewählt ist aus Fettsäuren, solche sind insbesondere ausgewählt aus linearen, gesättigten, unsubstituierten Carbonsäuren.
Insbesondere sind erfindungsgemäß Zusammensetzungen bevorzugt, die dadurch gekennzeichnet sind, dass die Carbonsäure a) ausgewählt ist aus Caprylsäure und Caprinsäure, die Carbonsäure b) ausgewählt ist aus Stearinsäure und Palmitinsäure und die Carbonsäure c) Behensäure ist.
A composition preferred according to the invention is characterized in that after its complete hydrolysis, the polyglycerol ester averages (number average) per mole of polyglycerol ester
from 0.01 to 0.07 mol, preferably from 0.01 to 0.50 mol, particularly preferably from 0.01 to 0.30 mol, of at least one carboxylic acid a)
from 0.10 to 1.70 mol, preferably from 0.30 to 1.50 mol, particularly preferably from 0.40 to 1.40 mol, of at least one carboxylic acid b)
from 0.01 to 0.80 mol, preferably from 0.01 to 0.60 mol, particularly preferably from 0.05 to 0.40 mol, of at least one carboxylic acid c)
releases.
In particular, it is characterized in that the molar ratio of the carboxylic acid a) to carboxylic acid b) to carboxylic acid c) obtained after complete hydrolysis of the polyglycerol ester
0.6 to 1.4: 16.5 to 20.5: 3.0 to 4.8, preferred
0.8 to 1.2: 17.5 to 19.5: 3.5 to 4.3, particularly preferred
0.9 to 1.1: 18.0 to 19.0: 3.7 to 4.1.
The method described above can be used as a method to determine the molar ratios.
It is preferred according to the invention that the carboxylic acids a), b) and c) are selected from fatty acids; those are in particular selected from linear, saturated, unsubstituted carboxylic acids.
In particular, compositions according to the invention are preferred which are characterized in that the carboxylic acid a) is selected from caprylic acid and capric acid, the carboxylic acid b) is selected from stearic acid and palmitic acid and the carboxylic acid c) is behenic acid.

Hydroxy-alkylmodifiziertes Guar ist vielfach beschrieben und beispielsweise als Esaflor HM 22 kommerziell erhältlich. Guar ist ein Galaktomannan, in welches langekttige Hydroxy-Alkylmodifikationen einfach durch Umsetzung mit Epoxyalkanen eingefügt werden können.
Erfindungsgemäß bevorzugte Zusammensetzungen enthalten hydroxy-alkylmodifziertes Guar, welches mit Alkylgruppen mit 16 bis 24, bevorzugt 18 bis 22, Kohlenstoffatomen modifiziert ist.
Es ist erfindungsgemäß bevorzugt, dass das hydroxy-alkylmodifzierte Guar zusätzlich hydroxypropyl modifiziert, ist. Ein erfindungsgemäß besonders bevorzugt enthaltenes Guar ist der nach INCI benannte Stoff C18-C22 Hydroxyalkyl Hydroxypropyl Guar. Hydroxy-alkylmodifiziertes Guar und solches, welches zusätzlich hydroxypropyl modifiziert ist, sowie Verfahren zur Herstellung dieser Verbindungen sind beispielsweise in derUS4960876 beschrieben.
Hydroxy-alkyl-modified guar has been widely described and is commercially available, for example, as Esaflor HM 22. Guar is a galactomannan, into which long-term hydroxy alkyl modifications can be inserted simply by reaction with epoxyalkanes.
Compositions preferred according to the invention contain hydroxy-alkyl-modified guar which is modified with alkyl groups having 16 to 24, preferably 18 to 22, carbon atoms.
It is preferred according to the invention that the hydroxy-alkyl-modified guar is additionally hydroxypropyl-modified. A guar which is particularly preferably contained according to the invention is the substance C18-C22 hydroxyalkyl hydroxypropyl guar named after INCI. Hydroxy-alkyl-modified guar and those which are additionally hydroxypropyl-modified, and processes for the preparation of these compounds are, for example, in US Pat US4960876 described.

Die erfindungsgemäßen Zusammensetzungen sind hervorragend zur Formulierung von Deo oder AP-Deo-Zusammensetzungen (AP=Antiperspirant) geeignet, daher enthalten sie bevorzugt zusätzlich C) mindestens einen ausgewählt aus Deo-Wirkstoff und AP-Wirkstoff, insbesondere mindestens einen Deo-Wirkstoff und mindestens einen AP-Wirkstoff.The compositions according to the invention are outstandingly suitable for the formulation of deodorant or AP deodorant compositions (AP = antiperspirant), therefore they preferably additionally contain C) at least one selected from deodorant active ingredient and AP active ingredient, in particular at least one deodorant active ingredient and at least one AP agent.

Es ist erfindungsgemäß bevorzugt, dass der AP-Wirkstoff ausgewählt ist aus der Gruppe umfassen, bevorzugt bestehend aus, Aluminium-Salzen und Zirkonium-Salzen. Es sind insbesondere erfindungsgemäße Zusammensetzungen bevorzugt, die dadurch gekennzeichnet sind, dass das Aluminium-Salz ausgewählt ist aus der Gruppe umfassend, bevorzugt bestehend aus:
Aluminum Acetate, Aluminum Behenate, Aluminum Benzoate, Aluminum Bromohydrate, Aluminum Butoxide, Aluminum Calcium Sodium Silicate, Aluminum Caprylate, Aluminum Capryloyl Hydrolyzed Collagen, Aluminum Chloride, Aluminiumchlorohydrat, Aluminum Chlorohydrex, Aluminum Chlorohydrex PEG, Aluminum Chlorohydrex PG, Aluminum Citrate, Aluminum Diacetate, Aluminum Dibenzoate/Stearate Hydroxide, Aluminum Dicetyl Phosphate, Aluminum Dichlorohydrate, Aluminum Dichlorohydrex PEG, Aluminum Dichlorohydrex PG, Aluminum Dilinoleate, Aluminum Dimyristate, Aluminum Distearate, Aluminum Glycinate, Aluminum Hydrogenated Tallow Glutamate, Aluminum Hydroxy Bis-Methylene Bis-Di-t-Butylphenyl Phosphate, Aluminum Iron Calcium Magnesium Germanium Silicates, Aluminum Iron Calcium Magnesium Zirconium Silicates, Aluminum Iron Silicates, Aluminum Isopropoxide, Aluminum Isostearate, Aluminum Isostearates/Laurates/Palmitates, Aluminum Isostearates/Laurates/Stearates, Aluminum Isostearates/Myristates, Aluminum Isostearates/Palmitates, Aluminum Isostearates/Stearates, Aluminum Isostearyl Glyceryl Phosphate, Aluminum Laccate, Aluminum Lactate, Aluminum Lanolate, Aluminum/Magnesium Hydroxide Stearate, Aluminum Magnesium Oxide, Aluminum Methionate, Aluminum Myristate, Aluminum Myristates/Palmitates, Aluminum PCA, Aluminum Phenolsulfonate, Aluminum Sesquichlorohydrate, Aluminum Sesquichlorohydrex PEG, Aluminum Sesquichlorohydrex PG, Aluminum Starch Octenylsuccinate, Aluminum Stearate, Aluminum Stearates, Aluminum Stearoyl Glutamate, Aluminum Sucrose Octasulfate, Aluminum Sulfate, Aluminum Triformate, Aluminum Triphosphate, Aluminum Tristearate, Aluminum Undecylenoyl Collagen Amino Acids, Aluminum Zinc Oxide, Aluminum Zirconium Trichlorohydrate, Aluminum Zirconium Trichlorohydrex GLY, Aluminum Zirconium Tetrachlorohydrate, Aluminium Zirconium Tetrachlorohydrex GLY, Aluminum Zirconium Tetrachlorohydrex PEG, Aluminum Zirconium Tetrachlorohydrex PG, Aluminium Zirconium Pentachlorohydrat, Aluminum Zirconium Pentachlorohydrex GLY, Aluminum Zirconium Octachlorohydrate, Aluminum Zirconium Octachlorohydrex GLY, Ammonium Alum, Ammonium Silver Zinc Aluminum Silicate, Calcium Aluminum Borosilicate, Cobalt Aluminum Oxide, Magnesium/Aluminum/Hydroxide/Carbonate, Magnesium Aluminum Silicate, Magnesium/Aluminum/Zinc/Hydroxide/Carbonate, Potassium Alum, Potassium Aluminum Polyacrylate, Silver Magnesium Aluminum Phosphate, Sodium Alum, Sodium Aluminate, Sodium Aluminum Chlorohydroxy Lactate, Sodium/Aluminum Hydroxide/Oxalate/Sulfate, Sodium/Aluminum/Iron Hydroxide/Oxalate/Sulfate, Sodium/Aluminum/Iron/Sulfate/Citrate/Hydroxide, Sodium/Aluminum/Iron/Sulfate/Oxalate/Hydroxide,
Sodium/Aluminum/Iron/Sulfate/Tartarate/Hydroxide, Sodium Aluminum Lactate, Sodium Phosphorus/Zinc/Calcium/Silicon/Aluminum/Silver Oxides, Sodium Potassium Aluminum Silicate, Sodium Silicoaluminate, Sodium Silver Aluminum Silicate, Tromethamine Magnesium Aluminum Silicate und Alaun, insbesondere Aluminiumchlorohydrat.
Unter dem Begriff "Aluminiumchlorohydrat" werden im Zusammenhang mit der vorliegenden Erfindung die Salze der allgemeinen Summenformel AlnCl(3n-m)(OH)m, insbesondere Al2Cl(OH)5, verstanden.
Geeignete Zirkonium-Salze sind ausgewählt aus den inUS20070071701,US3792068 undUS2854382 beschriebenen zirkoniumhaltigen Verbindungen.
It is preferred according to the invention that the AP active ingredient is selected from the group comprising, preferably consisting of, aluminum salts and zirconium salts. Compositions according to the invention are particularly preferred which are characterized in that the aluminum salt is selected from the group comprising, preferably consisting of:
Aluminum Acetate, Aluminum Behenate, Aluminum Benzoate, Aluminum Bromohydrate, Aluminum Butoxide, Aluminum Calcium Sodium Silicate, Aluminum Caprylate, Aluminum Capryloyl Hydrolyzed Collagen, Aluminum Chloride, Aluminum Chlorohydrate, Aluminum Chlorohydrex, Aluminum Chlorohydrex PEG, Aluminum Chlorohydrex PG, Aluminum Citrate, Aluminum Diacetate, Aluminum Dibenzoate / Stearate Hydroxide, Aluminum Dicetyl Phosphate, Aluminum Dichlorohydrate, Aluminum Dichlorohydrex PEG, Aluminum Dichlorohydrex PG, Aluminum Dilinoleate, Aluminum Dimyristate, Aluminum Distearate, Aluminum Glycinate, Aluminum Hydrogenated Tallow Glutamate, Aluminum Hydroxy Bis-Methylene Bis-Di-t-Butylphenyl Phosphate, Aluminum Iron Calcium Magnesium Germanium Silicates, Aluminum Iron Calcium Magnesium Zirconium Silicates, Aluminum Iron Silicates, Aluminum Isopropoxide, Aluminum Isostearate, Aluminum Isostearates / Laurates / Palmitates, Aluminum Isostearates / Laurates / Stearates, Aluminum Isostearates / Myristates, Aluminum Isosteara tes / Palmitates, Aluminum Isostearates / Stearates, Aluminum Isostearyl Glyceryl Phosphate, Aluminum Laccate, Aluminum Lactate, Aluminum Lanolate, Aluminum / Magnesium Hydroxide Stearate, Aluminum Magnesium Oxide, Aluminum Methionate, Aluminum Myristate, Aluminum Myristates / Palmitates, Aluminum PCA, Aluminum Phenolsulfonate, Aluminum Sesquichlorohydrate, Aluminum Sesquichlorohydrex PEG, Aluminum Sesquichlorohydrex PG, Aluminum Starch Octenylsuccinate, Aluminum Stearate, Aluminum Stearates, Aluminum Stearoyl Glutamate, Aluminum Sucrose Octasulfate, Aluminum Sulfate, Aluminum Triformate, Aluminum Triphosphate, Aluminum Tristearids, Aluminum Zinc Oxide Acid, Aluminum Zinc Oxide Acid , Aluminum Zirconium Trichlorohydrate, Aluminum Zirconium Trichlorohydrex GLY, Aluminum Zirconium Tetrachlorohydrate, Aluminum Zirconium Tetrachlorohydrex GLY, Aluminum Zirconium Tetrachlorohydrex PEG, Aluminum Zirconium Tetrachlorohydrex PG, Aluminum Zirconium Pentachlorohydrat, Aluminum Zirconium Pe ntachlorohydrex GLY, Aluminum Zirconium Octachlorohydrate, Aluminum Zirconium Octachlorohydrex GLY, Ammonium Alum, Ammonium Silver Zinc Aluminum Silicate, Calcium Aluminum Borosilicate, Cobalt Aluminum Oxide, Magnesium / Aluminum / Hydroxide / Carbonate, Magnesium Aluminum Silicate, Magnesium / Aluminum / Zinc / Hydroxide / Carbonate , Potassium Alum, Potassium Aluminum Polyacrylate, Silver Magnesium Aluminum Phosphate, Sodium Alum, Sodium Aluminate, Sodium Aluminum Chlorohydroxy Lactate, Sodium / Aluminum Hydroxide / Oxalate / Sulfate, Sodium / Aluminum / Iron Hydroxide / Oxalate / Sulfate, Sodium / Aluminum / Iron / Sulfate / Citrate / hydroxides, Sodium / Aluminum / Iron / Sulfate / oxalate / hydroxides,
Sodium / Aluminum / Iron / Sulfate / Tartarate / Hydroxide, Sodium Aluminum Lactate, Sodium Phosphorus / Zinc / Calcium / Silicon / Aluminum / Silver Oxides, Sodium Potassium Aluminum Silicate, Sodium Silicoaluminate, Sodium Silver Aluminum Silicate, Tromethamine Magnesium Aluminum Silicate and Alum, especially aluminum chlorohydrate.
In connection with the present invention, the term “aluminum chlorohydrate” means the salts of the general empirical formula Aln Cl(3n-m ) (OH)m , in particular Al2 Cl (OH)5 .
Suitable zirconium salts are selected from the in US20070071701 . US3792068 and US2854382 described zirconium-containing compounds.

Geeignete Deo-Wirkstoffe sind ausgewählt aus der Gruppe umfassend, bevorzugt bestehend aus den inEP2421614 genannten Deodorantien und keimhemmenden Mitteln sowie Zink-Salzen.
Erfindungsgemäß bevorzugt ist das Zink-Salz ausgewählt aus der Gruppe der Zink-Salze der Essigsäure, Milchsäure, Oxalsäure, Bernsteinsäure, Fumarsäure, Maleinsäure, Ricinolsäure und/oder Citronensäure gewählt werden.
Suitable deodorant active ingredients are selected from the group comprising, preferably consisting of the in EP2421614 deodorants and antiseptic agents and zinc salts.
According to the invention, the zinc salt is preferably selected from the group of the zinc salts of acetic acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, ricinoleic acid and / or citric acid.

Die erfindungsgemäßen Zusammensetzungen stabilisieren insbesondere Emulsionen, so dass eine erfindungsgemäß bevorzugte Zusammensetzung dadurch gekennzeichnet ist, dass sie eine Emulsion, insbesondere eine Öl-in-Wasser-Emulsion ist.
Erfindungsgemäß bevorzugte Emulsion enthalten bezogen auf die Gesamtemulsion von 0,1 Gew.-% bis 60,0 Gew.-%, bevorzugt von 4,0 Gew.-% bis 30,0 Gew.-%, besonders bevorzugt von 5,0 Gew.-% bis 20,0 Gew.-%, mindestens ein Öl, insbesondere ein kosmetisches Öl.
Geeignete kosmetische Öle sind beispielsweise inDE10361202 aufgeführt.
Zur guten Emulsionsstabilität ist es bevorzugt, dass die erfindungsgemäßen Emulsionen bezogen auf die Gesamtemulsion von 0,1 Gew.-% bis 15,0 Gew.-%, bevorzugt von 0,5 Gew.-% bis 10,0 Gew.-%, besonders bevorzugt von 1,0 Gew.-% bis 7,0 Gew.-%, mindestens eines Emulgators enthalten.
Bevorzugt enthaltene Emulgatoren sind insbesondere Öl-in-Wasser-Emulgatoren, insbesondere inEP2421614 aufgeführte Emulgatoren.
The compositions according to the invention in particular stabilize emulsions, so that a composition preferred according to the invention is characterized in that it is an emulsion, in particular an oil-in-water emulsion.
Emulsions preferred according to the invention contain, based on the total emulsion, from 0.1% by weight to 60.0% by weight, preferably from 4.0% by weight to 30.0% by weight, particularly preferably from 5.0% by weight .-% to 20.0 wt .-%, at least one oil, in particular a cosmetic oil.
Suitable cosmetic oils are for example in DE10361202 listed.
For good emulsion stability, it is preferred that the emulsions according to the invention, based on the total emulsion, from 0.1% by weight to 15.0% by weight, preferably from 0.5% by weight to 10.0% by weight, particularly preferably from 1.0% by weight to 7.0% by weight, contain at least one emulsifier.
Emulsifiers preferably contained are in particular oil-in-water emulsifiers, in particular in EP2421614 listed emulsifiers.

Die erfindungsgemäßen Zusammensetzungen stabilisieren auch sonst schwierige Formulierungen, die eine niedrige Viskosität aufweisen, somit ist eine erfindungsgemäß bevorzugte Zusammensetzung dadurch gekennzeichnet, dass sie eine Viskosität in einem Bereich von 500 bis 20000, bevorzugt von 1500 bis 10000 mPas, aufweist, wobei die Viskosität bei 25 °C mit Brookfield RVT, Spindel 4, 5 UpM, gemessen wird.The compositions according to the invention also stabilize otherwise difficult formulations which have a low viscosity, so a composition preferred according to the invention is characterized in that it has a viscosity in a range from 500 to 20,000, preferably from 1,500 to 10,000 mPas, the viscosity at 25 ° C with Brookfield RVT, spindle 4, 5 rpm.

Insbesondere sind Zusammensetzungen bevorzugt, die im Wesentlichen polyglycoletherfrei und im Wesentlichen frei von alkoxylierten Verbindungen sind. Unter dem Begriff "im Wesentlichen frei von alkoxylierten Verbindungen" und "im Wesentlichen polyglycoletherfrei" im Zusammenhang mit der vorliegenden Erfindung ist zu verstehen, dass die Zusammensetzungen, mit gegebenenfalls der erfindungsgemäß enthaltenen Komponente B) als Ausnahme, keine nennenswerten Mengen an alkoxylierten oder polyglycolether enthaltende Verbindungen aufweist, die eine oberflächenaktive Wirkung ausüben. Insbesondere ist hierunter zu verstehen, dass diese Verbindungen in Mengen von kleiner 1 Gew.-%, bevorzugt von kleiner 0,1 Gew.-%, besonders bevorzugt von kleiner 0,01 Gew.-% bezogen auf die Gesamtzusammensetzung, insbesondere keine nachweisbaren Mengen, enthalten sind.In particular, compositions are preferred which are essentially free of polyglycol ether and essentially free of alkoxylated compounds. The term “essentially free of alkoxylated compounds” and “essentially free of polyglycol ether” in connection with the present invention is to be understood to mean that the compositions, with the exception of component B) according to the invention, as an exception, do not contain any appreciable amounts of alkoxylated or polyglycol ether Has compounds that have a surface-active effect. In particular, this means that these compounds in amounts of less than 1% by weight, preferably less than 0.1% by weight, particularly preferably less than 0.01% by weight, based on the total composition, in particular no detectable amounts , are included.

In den nachfolgend aufgeführten Beispielen wird die vorliegende Erfindung beispielhaft beschrieben, ohne dass die Erfindung, deren Anwendungsbreite sich aus der gesamten Beschreibung und den Ansprüchen ergibt, auf die in den Beispielen genannten Ausführungsformen beschränkt sein soll.In the examples listed below, the present invention is described by way of example, without the invention, the scope of which results from the entire description and the claims, being restricted to the embodiments mentioned in the examples.

Abbildung 1 zeigt Speichermodul und Verlustmodul für die nach erfindungsgemäßer Rezeptur 1-2 bzw. nicht erfindungsgemäßer Rezeptur 1-9 hergestellten Emulsionen.illustration 1 shows storage modulus and loss modulus for the emulsions produced according to formulation 1-2 according to the invention or formulation 1-9 not according to the invention.

Beispiele:Examples:Vorsynthesebeispiel 1 (Glycerylmonobehenat)Pre-Synthesis Example 1 (Glyceryl Monobehenate)

Ein Gemisch aus Glycerin (92 g, 1.0 mol), Behensäure (234.6 g, 0.69 mol) und Ca(OH)2 (0.06 g) wurde innerhalb von 3 h unter Stickstoffeinleitung bis auf 240 °C erhitzt und das Gemisch anschließend so lange bei dieser Temperatur gerührt und das entstehende Wasser kontinuierlich entfernt, bis eine Säurezahl von ≤1.5 erreicht war. Nach Abkühlen auf 90 °C wurde anschließend eine 5%ige Lösung von H3PO4 in Glycerin (2 g) zugegeben und das Reaktionsgemisch wieder auf 240 °C erhitzt. Ab einer Temperatur von ≥100 °C wurde der Druck bei gleichzeitiger Stickstoffeinleitung auf 10 mbar gesenkt und so lange destilliert, bis kein Destillat mehr anfiel. Nach Zugabe eines Filterhilfsmittels wird über einen Filter filtriert.A mixture of glycerol (92 g, 1.0 mol), behenic acid (234.6 g, 0.69 mol) and Ca (OH)2 (0.06 g) was brought up to 240 ° C. in the course of 3 h while introducing nitrogen heated and the mixture was then stirred at this temperature and the water formed was continuously removed until an acid number of ≤1.5 was reached. After cooling to 90 ° C., a 5% solution of H3 PO4 in glycerol (2 g) was then added and the reaction mixture was heated to 240 ° C. again. From a temperature of ≥100 ° C, the pressure was reduced to 10 mbar while simultaneously introducing nitrogen and distilled until no more distillate was obtained. After adding a filter aid, it is filtered through a filter.

Vorsynthesebeispiel 2 (Glycerylmonostearat)Pre-Synthesis Example 2 (Glyceryl Monostearate)

Ein Gemisch aus Glycerin (198,3 g, 2,15 mol), Stearinsäure und Palmitinsäure im Verhältnis 1:1 (401.8 g, 1.49 mol) und Ca(OH)2 (0.13 g) wurde innerhalb von 3 h unter Stickstoffeinleitung bis auf 240 °C erhitzt und das Gemisch anschließend so lange bei dieser Temperatur gerührt und das entstehende Wasser kontinuierlich entfernt, bis eine Säurezahl von ≤1.5 erreicht war. Nach Abkühlen auf 90 °C wurde anschließend eine 5%ige Lösung von H3PO4 in Glycerin (4.3 g) zugegeben und das Reaktionsgemisch wieder auf 240 °C erhitzt. Ab einer Temperatur von ≥100 °C wurde der Druck bei gleichzeitiger Stickstoffeinleitung auf 10 mbar gesenkt und so lange destilliert, bis kein Destillat mehr anfiel. Nach Zugabe eines Filterhilfsmittels wird über einen Filter filtriert.A mixture of glycerol (198.3 g, 2.15 mol), stearic acid and palmitic acid in a ratio of 1: 1 (401.8 g, 1.49 mol) and Ca (OH)2 (0.13 g) was stirred up to within 3 h with nitrogen Heated 240 ° C and the mixture was then stirred at this temperature and the water formed was continuously removed until an acid number of ≤1.5 was reached. After cooling to 90 ° C., a 5% solution of H3 PO4 in glycerol (4.3 g) was then added and the reaction mixture was heated again to 240 ° C. From a temperature of ≥100 ° C, the pressure was reduced to 10 mbar while simultaneously introducing nitrogen and distilled until no more distillate was obtained. After adding a filter aid, it is filtered through a filter.

Vorsynthesebeispiel 3 (Polyglyceryl-4-Stearat)Pre-synthesis example 3 (polyglyceryl-4-stearate)

Ein Gemisch aus Glycerin (2102 g, 22,8 mol) und 45%iger wässriger Kalilauge (24,2 g) wurde bei 400 mbar innerhalb von 1 Stunde auf 240 °C erhitzt und das entstehende Wasser kontinuierlich abdestilliert. Sobald das Reaktionsgemisch einen Brechungsindex von ≥1.4830 erreicht hatte, wurde der Druck langsam auf 50 mbar gesenkt und weiter Wasser sowie überschüssiges Glycerin bei 240 °C abdestilliert, bis das verbleibende Gemisch eine Hydroxylzahl von 990 mg KOH/g aufwies.
Ein Gemisch aus dem so erhaltenen Polyglycerin (252,2 g, 0,8 mol) und Stearinsäure und Palmitinsäure im Verhältnis 1:1 (97,8 g, 0,36 mol) wurde innerhalb von 3 h unter Stickstoffeinleitung bis auf 240 °C erhitzt und das Gemisch anschließend so lange bei dieser Temperatur gerührt und das entstehende Wasser kontinuierlich entfernt, bis eine Säurezahl von ≤1.0 erreicht war und das Gemisch bei 240 °C klar und homogen war.
A mixture of glycerol (2102 g, 22.8 mol) and 45% aqueous potassium hydroxide solution (24.2 g) was heated at 400 mbar to 240 ° C. within 1 hour and the water formed was distilled off continuously. As soon as the reaction mixture had reached a refractive index of ≥1.4830, the pressure was slowly reduced to 50 mbar and further water and excess glycerol were distilled off at 240 ° C. until the remaining mixture had a hydroxyl number of 990 mg KOH / g.
A mixture of the polyglycerol thus obtained (252.2 g, 0.8 mol) and stearic acid and palmitic acid in a ratio of 1: 1 (97.8 g, 0.36 mol) was brought up to 240 ° C. in the course of 3 h with nitrogen blowing heated and the mixture was then stirred at this temperature and the water formed was continuously removed until an acid number of ≤1.0 was reached and the mixture was clear and homogeneous at 240 ° C.

Vorsynthesebeispiel 4 (Polyglyceryl-3-Caprylat/Caprat)Pre-synthesis example 4 (polyglyceryl-3-caprylate /caprate)

Ein Gemisch aus kommerziell erhältlichem Polyglycerin-3 (Solvay; 240 g, 1 mol) und Caprylsäure und Caprinsäure im Verhältnis 60:40 (78,8 g, 0,5 mol) wurde innerhalb von 3 h unter Stickstoffeinleitung bis auf 240 °C erhitzt und das Gemisch anschließend so lange bei dieser Temperatur gerührt und das entstehende Wasser kontinuierlich entfernt, bis eine Säurezahl von ≤0.5 erreicht war.A mixture of commercially available polyglycerol-3 (Solvay; 240 g, 1 mol) and caprylic acid and capric acid in a ratio of 60:40 (78.8 g, 0.5 mol) was heated to 240 ° C. in the course of 3 h while introducing nitrogen and the mixture was then stirred at this temperature and the water formed was continuously removed until an acid number of ≤0.5 was reached.

Synthesebeispiel 1 (nicht erfindungsgemäß)Synthesis example 1 (not according to the invention)

Ein Gemisch aus Estern erhalten wie beschrieben in Vorsynthesebeispiel 1 (22,5 g), in Vorsynthesebeispiel 2 (34,5 g), in Vorsynthesebeispiel 3(88,5 g) und in Vorsynthesebeispiel 4 (4,5 g) wurde auf 80 °C erhitzt und das Gemisch anschließend für 3 h bei dieser Temperatur gerührt..
Der so erhaltene Polyglycerinester weist nach seiner vollständigen Hydrolyse einen Polymerisationsgrad des Polyglycerins von <3 auf.
A mixture of esters was obtained as described in pre-synthesis example 1 (22.5 g), in pre-synthesis example 2 (34.5 g), in pre-synthesis example 3 (88.5 g) and in pre-synthesis example 4 (4.5 g) at 80 ° C heated and the mixture was then stirred at this temperature for 3 h.
After complete hydrolysis, the polyglycerol ester thus obtained has a degree of polymerization of the polyglycerol of <3.

Vorsynthesebeispiel 5 (Polyglyceryl-6-Stearat)Pre-Synthesis Example 5 (Polyglyceryl 6 Stearate)

Ein Gemisch aus Glycerin (2102 g, 22,8 mol) und 45%iger wässriger Kalilauge (24,2 g) wurde bei 400 mbar innerhalb von 1 Stunde auf 240 °C erhitzt und das entstehende Wasser kontinuierlich abdestilliert. Sobald das Reaktionsgemisch einen Brechungsindex von ≥1.4830 erreicht hatte, wurde der Druck langsam auf 50 mbar gesenkt und weiter Wasser sowie überschüssiges Glycerin bei 240 °C abdestilliert, bis das verbleibende Gemisch eine Hydroxylzahl von 960 mg KOH/g aufwies.
Ein Gemisch aus dem so erhaltenen Polyglycerin (1008,7 g, 2,2 mol) und Stearinsäure und Palmitinsäure im Verhältnis 1:1 (391,3 g, 1,5 mol) wurde innerhalb von 3 h unter Stickstoffeinleitung bis auf 240 °C erhitzt und das Gemisch anschließend so lange bei dieser Temperatur gerührt und das entstehende Wasser kontinuierlich entfernt, bis eine Säurezahl von ≤1.0 erreicht war und das Gemisch bei 240 °C klar und homogen war.
A mixture of glycerol (2102 g, 22.8 mol) and 45% aqueous potassium hydroxide solution (24.2 g) was heated at 400 mbar to 240 ° C. within 1 hour and the water formed was distilled off continuously. As soon as the reaction mixture had a refractive index of ≥1.4830, the pressure was slowly reduced to 50 mbar and further water and excess glycerol were distilled off at 240 ° C. until the remaining mixture had a hydroxyl number of 960 mg KOH / g.
A mixture of the polyglycerol thus obtained (1008.7 g, 2.2 mol) and stearic acid and palmitic acid in a ratio of 1: 1 (391.3 g, 1.5 mol) was brought up to 240 ° C. in the course of 3 h with nitrogen blowing heated and the mixture was then stirred at this temperature and the water formed was continuously removed until an acid number of ≤1.0 was reached and the mixture was clear and homogeneous at 240 ° C.

Synthesebeispiel 2 (erfindungsgemäß)Synthesis example 2 (according to the invention)

Ein Gemisch aus Estern erhalten wie beschrieben in Vorsynthesebeispiel 1 (18,75 g), in Vorsynthesebeispiel 2 (32,25 g), in Vorsynthesebeispiel 5(94,5 g) und in Vorsynthesebeispiel 4 (4,5 g) wurde auf 80 °C erhitzt und das Gemisch anschließend für 3 h bei dieser Temperatur gerührt..
Der so erhaltene Polyglycerinester weist nach seiner vollständigen Hydrolyse einen Polymerisationsgrad des Polyglycerins von ca. 3,9 auf.
A mixture of esters was obtained as described in pre-synthesis example 1 (18.75 g), in pre-synthesis example 2 (32.25 g), in pre-synthesis example 5 (94.5 g) and in pre-synthesis example 4 (4.5 g) at 80 ° C heated and the mixture was then stirred at this temperature for 3 h.
After complete hydrolysis, the polyglycerol ester thus obtained has a degree of polymerization of the polyglycerol of approximately 3.9.

Vorsynthesebeispiel 6 (Polyglyceryl-10-Stearat)Pre-Synthesis Example 6 (Polyglyceryl 10 Stearate)

Ein Gemisch aus Glycerin (2102 g, 22,8 mol) und 45%iger wässriger Kalilauge (24,2 g) wurde bei 400 mbar innerhalb von 1 Stunde auf 240 °C erhitzt und das entstehende Wasser kontinuierlich abdestilliert. Sobald das Reaktionsgemisch einen Brechungsindex von ≥1.4830 erreicht hatte, wurde der Druck langsam auf 50 mbar gesenkt und weiter Wasser sowie überschüssiges Glycerin bei 240 °C abdestilliert, bis das verbleibende Gemisch eine Hydroxylzahl von 875 mg KOH/g aufwies.
Ein Gemisch aus dem so erhaltenen Polyglycerin (252,2 g, 0,33 mol) und Stearinsäure und Palmitinsäure im Verhältnis 1:1 (97,8 g, 0,36 mol) wurde innerhalb von 3 h unter Stickstoffeinleitung bis auf 240 °C erhitzt und das Gemisch anschließend so lange bei dieser Temperatur gerührt und das entstehende Wasser kontinuierlich entfernt, bis eine Säurezahl von ≤1.0 erreicht war und das Gemisch bei 240 °C klar und homogen war.
A mixture of glycerol (2102 g, 22.8 mol) and 45% aqueous potassium hydroxide solution (24.2 g) was heated at 400 mbar to 240 ° C. within 1 hour and the water formed was distilled off continuously. As soon as the reaction mixture had reached a refractive index of ≥ 1.4830, the pressure was slowly reduced to 50 mbar and water and excess glycerol were further distilled off at 240 ° C. until the remaining mixture had a hydroxyl number of 875 mg KOH / g.
A mixture of the polyglycerol thus obtained (252.2 g, 0.33 mol) and stearic acid and palmitic acid in a ratio of 1: 1 (97.8 g, 0.36 mol) was brought up to 240 ° C. in the course of 3 h with nitrogen blowing heated and the mixture was then stirred at this temperature and the water formed was continuously removed until an acid number of ≤1.0 was reached and the mixture was clear and homogeneous at 240 ° C.

Vorsynthesebeispiel 7 (Polyglyceryl-10-Caprylat/Caprat)Pre-Synthesis Example 7 (Polyglyceryl 10 Caprylate /Caprat)

Ein Polyglycerin erhalten wie beschrieben in Beispiel 5a (240 g; 0,32 mol) und Caprylsäure und Caprinsäure im Verhältnis 60:40 (78,8 g, 0,5 mol) wurde innerhalb von 3 h unter Stickstoffeinleitung bis auf 240 °C erhitzt und das Gemisch anschließend so lange bei dieser Temperatur gerührt und das entstehende Wasser kontinuierlich entfernt, bis eine Säurezahl von ≤1.0 erreicht war.A polyglycerol obtained as described in Example 5a (240 g; 0.32 mol) and caprylic acid and capric acid in a ratio of 60:40 (78.8 g, 0.5 mol) were heated to 240 ° C. in the course of 3 h while introducing nitrogen and then the mixture stirred at this temperature and the water formed was continuously removed until an acid number of ≤1.0 was reached.

Synthesebeispiel 3 (erfindungsgemäß)Synthesis example 3 (according to the invention)

Ein Gemisch aus Estern erhalten wie beschrieben in Vorsynthesebeispiel 1 (18,8 g), in Vorsynthesebeispiel 2 (32,7 g), in Vorsynthesebeispiel 6 (93,8 g) und in Vorsynthesebeispiel 7(4,7 g) wurde auf 80 °C erhitzt und das Gemisch anschließend für 3 h bei dieser Temperatur gerührt.
Der so erhaltene Polyglycerinester weist nach seiner vollständigen Hydrolyse einen Polymerisationsgrad des Polyglycerins von ca. 4,5 auf.
A mixture of esters was obtained as described in pre-synthesis example 1 (18.8 g), in pre-synthesis example 2 (32.7 g), in pre-synthesis example 6 (93.8 g) and in pre-synthesis example 7 (4.7 g) C heated and the mixture was then stirred at this temperature for 3 h.
After complete hydrolysis, the polyglycerol ester thus obtained has a degree of polymerization of the polyglycerol of approximately 4.5.

Vorsynthesebeispiel 8Pre-synthesis example 8

Ein Gemisch aus Glycerin (2102 g, 22,8 mol) und 45%iger wässriger Kalilauge (24,2 g) wurde bei 400 mbar innerhalb von 1 Stunde auf 240 °C erhitzt und das entstehende Wasser kontinuierlich abdestilliert. Sobald das Reaktionsgemisch einen Brechungsindex von ≥1.4830 erreicht hatte, wurde der Druck langsam auf 50 mbar gesenkt und weiter Wasser sowie überschüssiges Glycerin bei 240 °C abdestilliert, bis das verbleibende Gemisch eine Hydroxylzahl von 924 mg KOH/g aufwies.
Ein Gemisch aus dem so erhaltenen Polyglycerin (231,9 g, 0,296 mol) und Stearinsäure und Palmitinsäure im Verhältnis 1:1 (85,42 g, 0,32 mol) und Caprylsäure und Caprinsäure im Verhältnis 60:40 (3,82 g, 0,025 mol) wurde innerhalb von 3 h unter Stickstoffeinleitung bis auf 240 °C erhitzt und das Gemisch anschließend so lange bei dieser Temperatur gerührt und das entstehende Wasser kontinuierlich entfernt, bis eine Säurezahl von ≤1.0 erreicht war und das Gemisch bei 240 °C klar und homogen war.
A mixture of glycerol (2102 g, 22.8 mol) and 45% aqueous potassium hydroxide solution (24.2 g) was heated at 400 mbar to 240 ° C. within 1 hour and the water formed was distilled off continuously. As soon as the reaction mixture had reached a refractive index of ≥1.4830, the pressure was slowly reduced to 50 mbar and water and excess glycerol were further distilled off at 240 ° C. until the remaining mixture had a hydroxyl number of 924 mg KOH / g.
A mixture of the polyglycerol thus obtained (231.9 g, 0.296 mol) and stearic acid and palmitic acid in a ratio of 1: 1 (85.42 g, 0.32 mol) and caprylic acid and capric acid in a ratio of 60:40 (3.82 g , 0.025 mol) was heated to 240 ° C. in the course of 3 hours with nitrogen injection and the mixture was then stirred at this temperature and the water formed was continuously removed until an acid number of ≤1.0 was reached and the mixture was clear at 240 ° C. and was homogeneous.

Synthesebeispiel 4 (erfindungsgemäß)Synthesis example 4 (according to the invention)

Ein Gemisch aus Estern erhalten wie beschrieben in Vorsynthesebeispiel 1 (18,75 g), in Vorsynthesebeispiel 2 (33,75 g) und in Vorsynthesebeispiel 8(97,5 g) wurde auf 80 °C erhitzt und das Gemisch anschließend für 3 h bei dieser Temperatur gerührt. Der so erhaltene Polyglycerinester weist nach seiner vollständigen Hydrolyse einen Polymerisationsgrad des Polyglycerins von ca. 3,6 auf.A mixture of esters obtained as described in pre-synthesis example 1 (18.75 g), in pre-synthesis example 2 (33.75 g) and in pre-synthesis example 8 (97.5 g) was heated to 80 ° C. and the mixture was then stirred for 3 hours this temperature stirred. After complete hydrolysis, the polyglycerol ester thus obtained has a degree of polymerization of the polyglycerol of approximately 3.6.

Vorsynthesebeispiel 9Pre-synthesis example 9

Ein Gemisch aus Glycerin (2102 g, 22,8 mol) und 45%iger wässriger Kalilauge (24,2 g) wurde bei 400 mbar innerhalb von 1 Stunde auf 240 °C erhitzt und das entstehende Wasser kontinuierlich abdestilliert. Sobald das Reaktionsgemisch einen Brechungsindex von ≥1.4830 erreicht hatte, wurde der Druck langsam auf 50 mbar gesenkt und weiter Wasser sowie überschüssiges Glycerin bei 240 °C abdestilliert, bis das verbleibende Gemisch eine Hydroxylzahl von 884 mg KOH/g aufwies.
Ein Gemisch aus dem so erhaltenen Polyglycerin (243,5 g, 0,32 mol) und Stearinsäure und Palmitinsäure im Verhältnis 1:1 (85,42 g, 0,32 mol) und Caprylsäure und Caprinsäure im Verhältnis 60:40 (3,82 g, 0,025 mol) wurde innerhalb von 3 h unter Stickstoffeinleitung bis auf 240 °C erhitzt und das Gemisch anschließend so lange bei dieser Temperatur gerührt und das entstehende Wasser kontinuierlich entfernt, bis eine Säurezahl von ≤1.0 erreicht war und das Gemisch bei 240 °C klar und homogen war.
A mixture of glycerol (2102 g, 22.8 mol) and 45% aqueous potassium hydroxide solution (24.2 g) was heated at 400 mbar to 240 ° C. within 1 hour and the water formed was distilled off continuously. As soon as the reaction mixture had reached a refractive index of ≥1.4830, the pressure was slowly reduced to 50 mbar and further water and excess glycerol were distilled off at 240 ° C. until the remaining mixture had a hydroxyl number of 884 mg KOH / g.
A mixture of the polyglycerol thus obtained (243.5 g, 0.32 mol) and stearic acid and palmitic acid in a ratio of 1: 1 (85.42 g, 0.32 mol) and caprylic acid and capric acid in a ratio of 60:40 (3, 82 g, 0.025 mol) was heated to 240 ° C. in the course of 3 hours while introducing nitrogen and the mixture was then stirred at this temperature and the water formed was continuously removed until an acid number of ≤1.0 was reached and the mixture at 240 ° C was clear and homogeneous.

Synthesebeispiel 5 (erfindungsgemäß)Synthesis example 5 (according to the invention)

Ein Gemisch aus Estern erhalten wie beschrieben in Vorsynthesebeispiel 1 (18,75 g), in Vorsynthesebeispiel 2 (33,75 g) und in Vorsynthesebeispiel 8(97,5 g) wurde auf 80 °C erhitzt und das Gemisch anschließend für 3 h bei dieser Temperatur gerührt. Der so erhaltene Polyglycerinester weist nach seiner vollständigen Hydrolyse einen Polymerisationsgrad des Polyglycerins von ca. 3,8 auf.A mixture of esters obtained as described in pre-synthesis example 1 (18.75 g), in pre-synthesis example 2 (33.75 g) and in pre-synthesis example 8 (97.5 g) was heated to 80 ° C. and the mixture was then stirred for 3 hours this temperature stirred. After complete hydrolysis, the polyglycerol ester thus obtained has a degree of polymerization of the polyglycerol of approximately 3.8.

Anwendungsbeispiele erfindungsgemäßer Zusammensetzungen vs. nicht erfindungsgemäßer Zusammensetzungen:Application examples of compositions according to the invention vs. Compositions not according to the invention:

Alle Konzentrationen in den Anwendungsbeispielen sind in Gewichtsprozent angegeben. Zur Herstellung der Emulsionen wurden dem Fachmann bekannte übliche Homogenisierverfahren eingesetzt.
Die Herstellung der Emulsionen erfolgte daher typischerweise so, dass Öl- und Wasserphase auf 70 - 75°C erwärmt wurden. Anschließend wurde entweder die Ölphase in die Wasserphase eingerührt oder Öl- und Wasserphase ohne Rühren zusammengegeben. Anschließend wurde mit einem geeigneten Homogenisator (z.B. Ultra Turrax) für ca. 1-2 Minuten homogenisiert.
Stabilisierende Polymere wurden entweder als Bestandteil der Ölphase (z.B. Guarderivate) oder als wässrige Suspension (z.B. Cellulosederivate) bei Temperaturen von 50 - 60°C in die Emulsion eingerührt. Anschließend wurde kurz homogenisiert. Zugabe weiterer Inhaltsstoffe (z.B. Konservierungsmittel, Wirkstoffe) erfolgte bevorzugt bei 40°C. Falls die Rezepturen mit organischen Säuren konserviert wurden, wurde der pH-Wert der Emulsionen auf ca. 5 eingestellt.
All concentrations in the application examples are given in percent by weight. Conventional homogenization processes known to those skilled in the art were used to prepare the emulsions.
The emulsions were therefore typically prepared by heating the oil and water phases to 70-75 ° C. The oil phase was then either stirred into the water phase or the oil and water phases were combined without stirring. The mixture was then homogenized with a suitable homogenizer (eg Ultra Turrax) for approx. 1-2 minutes.
Stabilizing polymers were either stirred into the emulsion as a component of the oil phase (eg guar derivatives) or as an aqueous suspension (eg cellulose derivatives) at temperatures of 50 - 60 ° C. The mixture was then briefly homogenized. Additional ingredients (eg preservatives, active ingredients) were preferably added at 40 ° C. If the formulations were preserved with organic acids, the pH of the emulsions was adjusted to approx. 5.

1) Differenzierung der Performance gegen den Stand der Technik1) Differentiation of performance against the state of the art

Diese Versuche zeigen, dass die erfindungsgemäßen Emulgatoren Vorteile in Bezug auf Emulsionsstabilität aufweisen. Als Repräsentanten für PEG-freie O/W Emulgator wurden dabei die Kombination aus Methyglucose Sesquistearat / Polyglyceryl-4 Laurat sowie Polyglyceryl-4 Laurate/Succinate (and) Aqua gewählt.
Zur Überprüfung der Lagerstabilität der Emulsionen wurden diese drei Monate bei Raumtemperatur und 40°C gelagert. Zur Überprüfung der Kältestabilität wurde außerdem ein Monat lang bei -5°C gelagert und drei Gefrier-Tau-Zyklen von 25°C/- 15°C/25°C durchgeführt. Deutliche Veränderungen im Erscheinungsbild oder der Konsistenz sowie insbesondere Öl- oder Wasserabscheidungen wurden als Kriterien für Instabilität gewichtet.A) Aluminiumsalzhaltige AP/Deo FormulierungRezeptur1-11-21-31-41-51-61-71-81-9Nicht erfindungsgem.erfindungsgem.erfindungsgem.Nicht erfindungsgem.Nicht erfindungsgem.Nicht erfindungsgem.Nicht erfindungsgem.Nicht erfindungsgem.Nicht erfindungsgem.Nicht erfindungsgem. Emulgator nach Synthesebeispiel 13,2Erfindungsgem. Emulgator nach Synthesebeispiel 23,23,2Erfindungsgem. Emulgator nach Synthesebeispiel 33,2Methylglucose Sesquistearate1)1,751,75Polyglyceryl-4 Laurate2)0,250,25Polyglyceryl-4 Laurate/Succinate (and) Aqua3)2,12,1Polyglyceryl-6 Stearate; Polyglyceryl-6 Behenate29)3,2C18-C22 Hydroxyalkyl Hydroxypropyl Guar4)0,20,20,20,50,50,2Hydroxyethylcellulose5)0,50,5Hydroxypropyl Guar30)0,2Isoamyl Cocoate6)5,45,45,47,07,05,45,45,45,4WasserAd 100Ad 100Ad 100Ad 100Ad 100Ad 100Ad 100Ad 100Ad 100Aluminum Chlorohydrate (50% aq.)720,020,020,015,015,020,020,020,020,0Methylisothiazolinone, Methylparaben, Ethylparaben; Dipropylene Glycol8)0,80,80,80,80,80,80,80,80,8Ist-pH4,24,24,24,24,24,24,24,24,2Viskosität [Pas] (Brookfield RVT, Spindel 4, 5 UpM)21592216"Wasserdünn""Wasserdünn"7"Wasserdünn"StabilitätNicht stabil, Wasserseparation nach 2 Tagen bei RTstabilstabilNicht stabil, Wasserseparation nach 2 Wochen bei RTNicht stabil, Wasserseparation nach 2 Tagen bei RTNicht stabil, Wasserseparation nach 2 Tagen bei RTNicht stabil, Wasserseparation nach 2 Tagen bei RTNicht stabil, Wasserseparation nach 1 Monat bei 40°C, bzw. nach 1 Monat bei - 5°CNicht stabil, Wasserseparation nach 2 Tagen bei RT1) TEGO Care PS (Evonik Industries AG)
2) TEGO Care PL 4 (Evonik Industries AG)
29) Polyglycerinester entsprechend Synthesebeispiel 1 inEP2705832
30) ESAFLOR HDR (Lamberti S.p.A.)
3) NatraGem E145 (Croda Int. Plc)
4) ESAFLOR HM 22 (Lamberti S.p.A.)
5) Natrosol 250 HHR (Ashland Specialty Ingredients)
6) TEGOSOFT AC (Evonik Industries AG)
7) Locron LIC (Clariant AG)
8) Microcare MEM (Thor)
B) Aluminiumfreie Deo-Formulierung ohne AP-WirkstoffeRezeptur2-12-22-32-42-52-62-72-82-9Nicht erf. Gem.Erf. Gem.Erf. Gem.Nicht erf. Gem.Nicht erf. Gem.Nicht erf. Gem.Nicht erf. Gem.Nicht erf. Gem.Nicht erf. Gem.Nicht erfindungsgem. Emulgator nach Synthesebeispiel 13,2Erfindungsgem. Emulgator nach Synthesebeispiel 23,2Erfindungsgem. Emulgator nach Synthesebeispiel 33,23,2Methylglucose Sesquistearate1)2,82,8Polyglyceryl-4 Laurate2)0,40,4Polyglyceryl-4 Laurate/Succinate (and) Aqua3)3,23,2Polyglyceryl-6 Stearate; Polyglyceryl-6 Behenate29)3,2C18-C22 Hydroxyalkyl Hydroxypropyl Guar4)0,150,150,150,150,150,15Hydroxyethylcellulose5)0,150,15Hydroxypropyl Guar30)0,15Polyglyceryl-3 Caprylate9)0,50,50,50,50,50,50,50,50,5Zinc Ricinoleate10)1,01,01,01,01,01,01,01,01,0Caprylic/Capric Triglyceride5,655,655,655,655,655,655,655,655,65WasserAd 100Ad 100Ad 100Ad 100Ad 100Ad 100Ad 100Ad 100Ad 100Glycerin3,03,03,03,03,03,03,03,03,0Benzyl Alcohol, Benzoic Acid, Sorbic Acid11)1,01,01,01,01,01,01,01,01,0Zitronensäure (50% aq.)q.s.q.s.q.s.q.s.q.s.q.s.q.s.q.s.q.s.pH5,05,05,05,05,05,05,05,05,0Viskosität [Pas] (Brookfield RVT, Spindel 4,5 UpM)7451810"was serdü nn""wass erdün n"22StabilitätNicht stabil, Wasserseparation nach 3 Monaten bei 40°Cstabilstabilzu hohe Visko sität, nicht gerfri ersta bil (-5°C und - 15°C)Nicht stabil, Wasserseparation bei Wärmela gerung (40°C )Nicht stabil, Phas entre nnung nach einem TagNicht stabil, Phas entre nnung nach einem TagNicht stabil, Wasserseparation nach 3 Monaten bei RTNicht stabil Wasserseparation nach 1 Monat bei 40°C9) TEGO Cosmo P 813 (Evonik Industries AG)
10) TEGODEO PY 88 G (Evonik Industries AG)
11) Rokonsal BSB-N (Ashland Specialty Ingredients)
C) O/W Deodorant-Emulsion enthaltend KalialaunRezeptur3-13-23-33-43-53-63-73-83-9Nicht Erf. Gem.Erf. Gem.Erf. Gem.Nicht Erf. Gem.Nicht Erf. Gem.Nicht Erf. Gem.Nicht Erf. Gem.Nicht Erf. Gem.Nicht Erf. Gem.Nicht erfindungsgem. Emulgator nach Synthesebeispiel 14,8Erfindungsgem. Emulgator nach Synthesebeispiel 24,84,8Erfindungsgem. Emulgator nach Synthesebeispiel 34,8Methylglucose Sesquistearate1)4,24,2Polyglyceryl-4 Laurate2)0,60,6Polyglyceryl-4 Laurate/Succinate (and) Aqua3)4,84,8Polyglyceryl-6 Stearate; Polyglyceryl-6 Behenate29)4,8C18-C22 Hydroxyalkyl Hydroxypropyl Guar4)0,250,250,250,250,250,25Hydroxyethylcellulose5)0,250,25Hydroxypropyl Guar30)0,25Isopropyl Palmitate5,05,05,05,05,05,05,05,05,0WasserAd 100Ad 100Ad 100Ad 100Ad 100Ad 100Ad 100Ad 100Ad 100Glycerin3,03,03,03,03,03,03,03,03,0Kalialaun5,05,05,05,05,05,05,05,05,0Methylisothiazoli none, Methylparaben, Ethylparaben; Dipropylene Glycol8)0,80,80,80,80,80,80,80,80,8Ist-pH3,43,43,43,43,43,43,43,43,4Viskosität [Pas] (Brookfield RVT, Spindel 4, 5 UpM)11 → 23334---11 → 34-Stabilitätzu starker Viskositäts anstieg währ end LagerungstabilstabilNicht stabil, Wasserseparation nach 1 Monatbei 40°CNicht stabil, Phas entre nnung 3h nach HerstellungNicht stabil, Phas entre nnung 3h nach HerstellungNicht stabil, Phas entre nnung 3h nach Herstellungzu starker Viskositätsanstieg währ end LagerungNicht stabil, Phas entre nnung 3h nach Herstellung
These tests show that the emulsifiers according to the invention have advantages in terms of emulsion stability. The combination of methyglucose sesquistearate / polyglyceryl-4 laurate and polyglyceryl-4 laurate / succinate (and) aqua was chosen as representatives for PEG-free O / W emulsifiers.
To check the storage stability of the emulsions, they were stored at room temperature and 40 ° C. for three months. To check the cold stability, storage was also carried out at -5 ° C for one month and three freeze-thaw cycles of 25 ° C / - 15 ° C / 25 ° C were carried out. Significant changes in appearance or consistency, and in particular oil or water deposits, were weighted as criteria for instability. A) AP / deodorant formulation containing aluminum salt recipe 1-1 1-2 1-3 1-4 1-5 1-6 1-7 1-8 1-9 Not according to the invention. invention. invention. Not according to the invention. Not according to the invention. Not according to the invention. Not according to the invention. Not according to the invention. Not according to the invention. Not according to the invention. Emulsifier according to synthesis example 1 3.2 Invention. Emulsifier according to synthesis example 2 3.2 3.2 Invention. Emulsifier according to synthesis example 3 3.2 Methyl glucose sesquistearate1) 1.75 1.75 Polyglyceryl-4 laurate2) 0.25 0.25 Polyglyceryl-4 Laurate / Succinate (and) Aqua3) 2.1 2.1 Polyglyceryl-6 stearates; Polyglyceryl-6 behenate29) 3.2 C18-C22 hydroxyalkyl hydroxypropyl guar4) 0.2 0.2 0.2 0.5 0.5 0.2 Hydroxyethyl cellulose5) 0.5 0.5 Hydroxypropyl guar30) 0.2 Isoamyl Cocoate6) 5.4 5.4 5.4 7.0 7.0 5.4 5.4 5.4 5.4 water Ad 100 Ad 100 Ad 100 Ad 100 Ad 100 Ad 100 Ad 100 Ad 100 Ad 100 Aluminum chlorohydrates (50% aq.)7 20.0 20.0 20.0 15.0 15.0 20.0 20.0 20.0 20.0 Methylisothiazolinones, methylparaben, ethylparaben; Dipropylene Glycol8) 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 Actual pH 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 Viscosity [Pas] (Brookfield RVT, spindle 4, 5 rpm) 21 5 9 22 16 "Water thin" "Water thin" 7 "Water thin" stability Not stable, water separation after 2 days at RT stable stable Not stable, water separation after 2 weeks at RT Not stable, water separation after 2 days at RT Not stable, water separation after 2 days at RT Not stable, water separation after 2 days at RT Not stable, water separation after 1 month at 40 ° C, or after 1 month at - 5 ° C Not stable, water separation after 2 days at RT1) TEGO Care PS (Evonik Industries AG)
2) TEGO Care PL 4 (Evonik Industries AG)
29) polyglycerol esters according to synthesis example 1 in EP2705832
30) ESAFLOR HDR (Lamberti SpA)
3) NatraGem E145 (Croda Int.Plc)
4) ESAFLOR HM 22 (Lamberti SpA)
5) Natrosol 250 HHR (Ashland Specialty Ingredients)
6) TEGOSOFT AC (Evonik Industries AG)
7) Locron LIC (Clariant AG)
8) Microcare MEM (Thor)
recipe 2-1 2-2 2-3 2-4 2-5 2-6 2-7 2-8 2-9 Not required acc. Req. Gem. Req. Gem. Not required acc. Not required acc. Not required acc. Not required acc. Not required acc. Not required acc. Not according to the invention. Emulsifier according to synthesis example 1 3.2 Invention. Emulsifier according to synthesis example 2 3.2 Invention. Emulsifier according to synthesis example 3 3.2 3.2 Methyl glucose sesquistearate1) 2.8 2.8 Polyglyceryl-4 laurate2) 0.4 0.4 Polyglyceryl-4 Laurate / Succinate (and) Aqua3) 3.2 3.2 Polyglyceryl-6 stearates; Polyglyceryl-6 behenate29) 3.2 C18-C22 hydroxyalkyl hydroxypropyl guar4) 0.15 0.15 0.15 0.15 0.15 0.15 Hydroxyethyl cellulose5) 0.15 0.15 Hydroxypropyl guar30) 0.15 Polyglyceryl-3 caprylates9) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 Zinc Ricinoleate10) 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 Caprylic / Capric triglycerides 5.65 5.65 5.65 5.65 5.65 5.65 5.65 5.65 5.65 water Ad 100 Ad 100 Ad 100 Ad 100 Ad 100 Ad 100 Ad 100 Ad 100 Ad 100 glycerin 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 Benzyl Alcohol, Benzoic Acid, Sorbic Acid11) 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 Citric acid (50% aq.) qs qs qs qs qs qs qs qs qs pH 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 Viscosity [Pas] (Brookfield RVT, spindle 4.5 rpm) 7 4 5 18 10 "what was thin" "water thin" 2 2 stability Not stable, water separation after 3 months at 40 ° C stable stable Viscosity too high, not resistant to rubbing (-5 ° C and - 15 ° C) Not stable, water separation when heated (40 ° C) Not stable, phase de-energization after one day Not stable, phase de-energization after one day Not stable, water separation after 3 months at RT Not stable water separation after 1 month at 40 ° C9) TEGO Cosmo P 813 (Evonik Industries AG)
10) TEGODEO PY 88 G (Evonik Industries AG)
11) Rokonsal BSB-N (Ashland Specialty Ingredients)
recipe 3-1 3-2 3-3 3-4 3-5 3-6 3-7 3-8 3-9 Not required Gem. Req. Gem. Req. Gem. Not required Gem. Not required Gem. Not required Gem. Not required Gem. Not required Gem. Not required Gem. Not according to the invention. Emulsifier according to synthesis example 1 4.8 Invention. Emulsifier according to synthesis example 2 4.8 4.8 Invention. Emulsifier according to synthesis example 3 4.8 Methyl glucose sesquistearate1) 4.2 4.2 Polyglyceryl-4 laurate2) 0.6 0.6 Polyglyceryl-4 Laurate / Succinate (and) Aqua3) 4.8 4.8 Polyglyceryl-6 stearates; Polyglyceryl-6 behenate29) 4.8 C18-C22 hydroxyalkyl hydroxypropyl guar4) 0.25 0.25 0.25 0.25 0.25 0.25 Hydroxyethyl cellulose5) 0.25 0.25 Hydroxypropyl guar30) 0.25 Isopropyl palmitate 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 water Ad 100 Ad 100 Ad 100 Ad 100 Ad 100 Ad 100 Ad 100 Ad 100 Ad 100 glycerin 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 potash alum 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 Methylisothiazoli none, methylparaben, ethylparaben; Dipropylene Glycol8) 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 Actual pH 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 Viscosity [Pas] (Brookfield RVT, spindle 4, 5 rpm) 11 → 23 3 3 4 - - - 11 → 34 - stability excessive viscosity increase during storage stable stable Not stable, water separation after 1 month at 40 ° C Not stable, phase separation 3 hours after manufacture Not stable, phase separation 3 hours after manufacture Not stable, phase separation 3 hours after manufacture Viscosity increases too much during storage Not stable, phase separation 3 hours after manufacture

In allen drei Vergleichsformulierungen aus dem Anwendungsbereich AP/Deo- bzw. Deo-Roll-on, welche verschiedene Wirkstoffe enthalten, erlauben die erfindungsgemäßen Emulgatoren die Formulierung einer stabilen Emulsion, wohingegen der nicht erfindungsgemäße Emulgator und die Repräsentanten des Stand der Technik keine stabile Emulsion ermöglichen. Die Verwendung von nicht erfindungsgemäß modifiziertem Guar führt ebenfalls zu nicht lagerstabilen Emulsionen.In all three comparative formulations from the AP / deodorant or deodorant roll-on area of application, which contain different active ingredients, the emulsifiers according to the invention allow the formulation of a stable emulsion, whereas the emulsifier not according to the invention and the representatives of the prior art do not enable a stable emulsion. The use of guar not modified according to the invention likewise leads to emulsions which are not stable in storage.

Formulierungen 1-2 und 1-9 wurden hinsichtlich ihrer Ausbildungsfähigkeit einer Fließgrenze untersucht. Die Messungen wurden mit einem Rheometer von Anton Paar, Modell MCR 301, Platte - Platte (40 mm) Geometrie mit einem Spalt von 1 mm bei einer Temperatur von 25°C und 1 bar Druck durchgeführt. Bestimmt wurden Speichermodul und Verlustmodul für die nach erfindungsgemäßer Rezeptur 1-2 bzw. nicht erfindungsgemäßer Rezeptur 1-9 hergestellten Emulsionen. Die Proben wurden bei konstanter Belastung von 0,20 Pa über den Frequenzbereich von 0,005 bis 90 Hz vermessen. Die rheologische Fließgrenze ist dadurch definiert, dass im vermessenen Frequenzbereich das Speichermodul (G') stets höhere Werte aufweist als das Verlustmodul (G") (sieheAbb. 1).Formulations 1-2 and 1-9 were examined for their ability to develop a yield point. The measurements were carried out with a rheometer from Anton Paar, model MCR 301, plate-plate (40 mm) geometry with a gap of 1 mm at a temperature of 25 ° C. and 1 bar pressure. The storage module and loss module were determined for the emulsions produced according to formulation 1-2 according to the invention or formulation 1-9 not according to the invention. The samples were measured at a constant load of 0.20 Pa over the frequency range from 0.005 to 90 Hz. The rheological yield point is defined by the fact that in the measured frequency range the memory module (G ') always has higher values than the loss module (G ") (see Fig. 1 ).

Weitere Anwendungsbeispiele außerhalb des AP/Deo Bereichs.
Diese Beispiele zeigen, dass die erfindungsgemäßen Zusammensetzungen in einer Vielzahl kosmetischer Formulierungen eingesetzt werden können.Sun Care Spray SPF 30Rezeptur4erfindungsgemäßer Emulgator nach Synthesebeispiel 44,0Phenoxyethyl Caprylate12)3,2Isopropyl Palmitate2,0Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine13)3,0Butyl Methoxydibenzoylmethane2,0EHC2,0Ethylhexylsalicylat4,0Octocrylene4,0Glycerin3,0Wasserad 100Carbomersuspension 114)1,0Tris(hydroxymethyl)-aminomethan (30% aq.)0,6UV-Filterlösung15)10,0Methylisothiazolinone, Methylparaben, Ethylparaben; Dipropylene Glycol8)0,811) TEGOSOFT XC (Evonik Industries AG)
13) Tinosorb S (BASF SE)
14) Acrylates/C10-30 Alkyl Acrylate Crosspolymer (TEGO Carbomer 341ER, Evonik Industries AG) 20%ig in Phenoxyethyl Caprylate
15) 20 % Phenylbenzimidazole Sulfonic Acid, 8,8% Tris (hydroxymethyl)-aminomethan, demineralisiertes Wasser ad 100%
KörperlotionRezeptur5erfindungsgemäßer Emulgator nach Synthesebeispiel 54,0Isoamyl Cocoate6)2,5Caprylic/Capric Triglyceride3,5Wasserad 100Creatine16)0,5Carbomersuspension 217)1,0Natriumhydroxid (10% aq.)0,6Phenoxyethanol, Ethylhexylglycerin18)0,716) TEGO Cosmo C 100 (Evonik Industries AG)
17) Carbomer (TEGO Carbomer 141, Evonik Industries AG) 20%ig in Ethylhexyl Stearate
18) Euxyl PE 9010 (Schülke & Mayr GmbH)
Natürliche PflegecremeRezeptur6erfindungsgemäßer Emulgator nach Synthesebeispiel 26,0Caprylic/Capric Triglyceride8,0Isopropyl Palmitate11,0Prunus Amygdalus Dulcis (Sweet Almond) Oil10,0Wasserad 100Glycerin3,0Natriumhydroxid (10% aq.)0,2Benzyl Alcohol, Benzoic Acid, Sorbic Acid11)0,8Anti-Aging CremeRezeptur7erfindungsgemäßer Emulgator nach Synthesebeispiel 46,0Caprylic/Capric Triglyceride9,5C12-15 Alkyl Benzoate9,5Wasserad 100Glycerin3,0Tetrapeptide-21; Glycerin; Butylene Glycol; Aqua19)4,0Sodium Hyaluronate20)0,1Hydrolyzed Hyaluronic Acid21)0,1Aqua; Ethylhexyl Stearate; Sodium Hyaluronate Cross polymer; Polyglyceryl-4 Diisostearate/Polyhydroxysteara te/Sebacate; Sodium Isostearate22)5,0Methylisothiazolinone, Methylparaben, Ethylparaben; Dipropylene Glycol8)0,819) TEGO PEP 4-17 (Evonik Industries)
20) HyaCare (Evonik Industries)
21) HyaCare 50 (Evonik Industries)
22) HyaCare Filler CL (Evonik Industries)
O/W FoundationRezeptur8erfindungsgemäßer Emulgator nach Synthesebeispiel 36,0Myristyl Myristate2,0Isopropyl Myristate6,0Decyl Cocoate6,0Cetyl Ricinoleate1,0Wasserad 100Glycerin1,0Titanium Dioxide23)8,0Iron Oxides24)0,9Iron Oxides25)0,2Iron Oxides26)0,4Iron Oxides27)0,1Cellulose28)2,0Natriumhydroxid (10% aq.)0,2Benzyl Alcohol, Benzoic Acid, Sorbic Acid11)1,023) Hombitan AC 360 (Sachtleben)
24) Sicovit Gelb 10 E 172 (Rockwood Pigments)
25) Sicovit Rot 30 E 172 (Rockwood Pigments)
26) Sicovit Braun 70 E 172 (Rockwood Pigments)
27) Sicovit Schwarz 80 E 172 (Rockwood Pigments)
28) TEGO Feel Green (Evonik Industries AG)
Further application examples outside of the AP / deodorant area.
These examples show that the compositions according to the invention can be used in a large number of cosmetic formulations. <i> Sun Care Spray SPF 30 </i> recipe 4 Emulsifier according to the invention according to synthesis example 4 4.0 Phenoxyethyl caprylate12) 3.2 Isopropyl palmitate 2.0 Bis-ethylhexyloxyphenol methoxyphenyl triazine13) 3.0 Butyl methoxydibenzoylmethane 2.0 EHC 2.0 ethylhexyl 4.0 Octocrylene 4.0 glycerin 3.0 water ad 100Carbomer suspension 114) 1.0 Tris (hydroxymethyl) aminomethane (30% aq.) 0.6 UV filter solution15) 10.0 Methylisothiazolinones, methylparaben, ethylparaben; Dipropylene Glycol8) 0.811) TEGOSOFT XC (Evonik Industries AG)
13) Tinosorb S (BASF SE)
14) Acrylates / C10-30 Alkyl Acrylate Crosspolymer (TEGO Carbomer 341ER, Evonik Industries AG) 20% in phenoxyethyl caprylate
15) 20% phenylbenzimidazole sulfonic acid, 8.8% tris (hydroxymethyl) aminomethane, demineralized water ad 100%
recipe 5 Emulsifier according to the invention according to synthesis example 5 4.0 Isoamyl Cocoate6) 2.5 Caprylic / Capric triglycerides 3.5 water ad 100 Creatine16) 0.5 Carbomer suspension 217) 1.0 Sodium hydroxide (10% aq.) 0.6 Phenoxyethanol, ethylhexylglycerol18) 0.716) TEGO Cosmo C 100 (Evonik Industries AG)
17) Carbomer (TEGO Carbomer 141, Evonik Industries AG) 20% in ethylhexyl stearate
18) Euxyl PE 9010 (Schülke & Mayr GmbH)
recipe 6 Emulsifier according to the invention according to synthesis example 2 6.0 Caprylic / Capric triglycerides 8.0 Isopropyl palmitate 11.0 Prunus Amygdalus Dulcis (Sweet Almond) Oil 10.0 water ad 100 glycerin 3.0 Sodium hydroxide (10% aq.) 0.2 Benzyl Alcohol, Benzoic Acid, Sorbic Acid11) 0.8 recipe 7 Emulsifier according to the invention according to synthesis example 4 6.0 Caprylic / Capric triglycerides 9.5 C12-15 alkyl benzoates 9.5 water ad 100 glycerin 3.0 Tetrapeptide-21; glycerol; Butylene glycol; Aqua19) 4.0 Sodium hyaluronate20) 0.1 Hydrolyzed Hyaluronic Acid21) 0.1 Aqua; Ethylhexyl stearate; Sodium hyaluronate cross polymer; Polyglyceryl-4 diisostearate / polyhydroxystearate / sebacate; Sodium isostearate22) 5.0 Methylisothiazolinones, methylparaben, ethylparaben; Dipropylene Glycol8) 0.819) TEGO PEP 4-17 (Evonik Industries)
20) HyaCare (Evonik Industries)
21) HyaCare 50 (Evonik Industries)
22) HyaCare Filler CL (Evonik Industries)
recipe 8th Emulsifier according to the invention from synthesis example 3 6.0 Myristyl myristate 2.0 Isopropyl myristate 6.0 Decyl Cocoate 6.0 Cetyl Ricinoleate 1.0 water ad 100 glycerin 1.0 Titanium Dioxide23) 8.0 Iron Oxides24) 0.9 Iron Oxides25) 0.2 Iron Oxides26) 0.4 Iron Oxides27) 0.1 Cellulose28) 2.0 Sodium hydroxide (10% aq.) 0.2 Benzyl Alcohol, Benzoic Acid, Sorbic Acid11) 1.023) Hombitan AC 360 (Sachtleben)
24) Sicovit Yellow 10 E 172 (Rockwood Pigments)
25) Sicovit Red 30 E 172 (Rockwood Pigments)
26) Sicovit Braun 70 E 172 (Rockwood Pigments)
27) Sicovit Black 80 E 172 (Rockwood Pigments)
28) TEGO Feel Green (Evonik Industries AG)

Claims (13)

  1. Composition comprising
    A) polyglycerol ester,
    which, after its complete hydrolysis, releases
    a) at least one carboxylic acid having 6 to 14, preferably 8 to 12, carbon atoms,
    b) at least one carboxylic acid having 16 to 20, preferably 18 to 20, carbon atoms,
    c) at least one carboxylic acid having 22 to 28, preferably 22 to 24, carbon atoms,
    and
    which, after its complete hydrolysis, releases a polyglycerol having an average degree of polymerization of from 3.0 to 5.0, preferably from 3.3 to 4.7, particularly preferably from 3.6 to 4.5,
    and
    B) at least one hydroxyalkyl-modified guar,characterized in that the hydroxyalkyl-modified guar has been modified with hydroxyalkyl groups having 12 to 26 carbon atoms.
  2. Composition according to Claim 1,characterized in that the polyglycerol ester, after its complete hydrolysis, releases an average (number average) per mole of polyglycerol ester of
    from 0.01 to 0.07 mol, preferably from 0.01 to 0.50 mol, particularly preferably from 0.01 to 0.30 mol, of at least one carboxylic acid a)
    from 0.10 to 1.70 mol, preferably from 0.30 to 1.50 mol, particularly preferably from 0.40 to 1.40 mol, of at least one carboxylic acid b)
    from 0.01 to 0.80 mol, preferably from 0.01 to 0.60 mol, particularly preferably from 0.05 to 0.40 mol, of at least one carboxylic acid c).
  3. Composition according to Claim 1 or 2,characterized in that the molar ratio of carboxylic acid a) to carboxylic acid b) to carboxylic acid c) obtained after complete hydrolysis of the polyglycerol ester is
    0.6 to 1.4:16.5 to 20.5:3.0 to 4.8, preferably
    0.8 to 1.2:17.5 to 19.5:3.5 to 4.3, particularly preferably 0.9 to 1.1:18.0 to 19.0:3.7 to 4.1.
  4. Composition according to at least one of the preceding claims,characterized in that the carboxylic acids a), b) and c) are selected from linear, saturated, unsubstituted carboxylic acids.
  5. Composition according to at least one of the preceding claims,characterized in that carboxylic acid a) is selected from caprylic acid and capric acid, carboxylic acid b) is selected from stearic acid and palmitic acid and carboxylic acid c) is behenic acid.
  6. Composition according to at least one of the preceding claims,characterized in that the polyglycerol released after complete hydrolysis of the polyglycerol ester has a mass ratio of glycerol to diglycerol of greater than 1, preferably greater than 1.2, particularly preferably greater than 1.4.
  7. Composition according to at least one of the preceding claims,characterized in that the hydroxyalkyl-modified guar is modified with hydroxyalkyl groups having 18 to 24, preferably 20 to 22, carbon atoms.
  8. Composition according to at least one of the preceding claims,characterized in that the hydroxyalkyl-modified guar has additionally been hydroxypropyl-modified.
  9. Composition according to at least one of the preceding claims,characterized in that said composition additionally comprises
    C) at least one selected from deodorant active ingredient and antiperspirant active ingredient.
  10. Composition according to at least one of the preceding claims,characterized in that the antiperspirant active ingredient is selected from the group comprising, preferably consisting of, aluminium salts and zirconium salts, and the deodorant active ingredient from the group of zinc salts, in particular aluminium chlorohydrate and zinc ricinoleate.
  11. Composition according to at least one of the preceding claims,characterized in that said composition is an emulsion, particularly an oil-in-water emulsion.
  12. Composition according to at least one of the preceding claims,characterized in that said composition has a viscosity in a range from 500 to 20 000, preferably 1500 to 10 000 mPas.
  13. Composition according to at least one of the preceding claims,characterized in that said composition is free from polyglycol ethers and free from alkoxylated compounds.
EP16151443.5A2016-01-152016-01-15Composition comprising polyglycerol esters and hydroxy-alkyl modified guarActiveEP3192491B1 (en)

Priority Applications (4)

Application NumberPriority DateFiling DateTitle
EP16151443.5AEP3192491B1 (en)2016-01-152016-01-15Composition comprising polyglycerol esters and hydroxy-alkyl modified guar
US15/380,137US20170202770A1 (en)2016-01-152016-12-15Composition comprising polyglycerol esters and hydroxyalkyl-modified guar
BR102017000660-3ABR102017000660B1 (en)2016-01-152017-01-12 COMPOSITION INCLUDING POLYGLYCEROL ESTERS AND GUAR GUM MODIFIED BY HYDROXYALKYL GROUPS
CN201710032429.2ACN107028795B (en)2016-01-152017-01-16Composition comprising polyglycerol ester and hydroxyalkyl modified guar gum

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
EP16151443.5AEP3192491B1 (en)2016-01-152016-01-15Composition comprising polyglycerol esters and hydroxy-alkyl modified guar

Publications (2)

Publication NumberPublication Date
EP3192491A1 EP3192491A1 (en)2017-07-19
EP3192491B1true EP3192491B1 (en)2020-01-08

Family

ID=55177758

Family Applications (1)

Application NumberTitlePriority DateFiling Date
EP16151443.5AActiveEP3192491B1 (en)2016-01-152016-01-15Composition comprising polyglycerol esters and hydroxy-alkyl modified guar

Country Status (4)

CountryLink
US (1)US20170202770A1 (en)
EP (1)EP3192491B1 (en)
CN (1)CN107028795B (en)
BR (1)BR102017000660B1 (en)

Families Citing this family (400)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20070084897A1 (en)2003-05-202007-04-19Shelton Frederick E IvArticulating surgical stapling instrument incorporating a two-piece e-beam firing mechanism
US9060770B2 (en)2003-05-202015-06-23Ethicon Endo-Surgery, Inc.Robotically-driven surgical instrument with E-beam driver
US8215531B2 (en)2004-07-282012-07-10Ethicon Endo-Surgery, Inc.Surgical stapling instrument having a medical substance dispenser
US11890012B2 (en)2004-07-282024-02-06Cilag Gmbh InternationalStaple cartridge comprising cartridge body and attached support
US9072535B2 (en)2011-05-272015-07-07Ethicon Endo-Surgery, Inc.Surgical stapling instruments with rotatable staple deployment arrangements
US11998198B2 (en)2004-07-282024-06-04Cilag Gmbh InternationalSurgical stapling instrument incorporating a two-piece E-beam firing mechanism
US7934630B2 (en)2005-08-312011-05-03Ethicon Endo-Surgery, Inc.Staple cartridges for forming staples having differing formed staple heights
US11484312B2 (en)2005-08-312022-11-01Cilag Gmbh InternationalStaple cartridge comprising a staple driver arrangement
US9237891B2 (en)2005-08-312016-01-19Ethicon Endo-Surgery, Inc.Robotically-controlled surgical stapling devices that produce formed staples having different lengths
US10159482B2 (en)2005-08-312018-12-25Ethicon LlcFastener cartridge assembly comprising a fixed anvil and different staple heights
US11246590B2 (en)2005-08-312022-02-15Cilag Gmbh InternationalStaple cartridge including staple drivers having different unfired heights
US7669746B2 (en)2005-08-312010-03-02Ethicon Endo-Surgery, Inc.Staple cartridges for forming staples having differing formed staple heights
US20070106317A1 (en)2005-11-092007-05-10Shelton Frederick E IvHydraulically and electrically actuated articulation joints for surgical instruments
US8186555B2 (en)2006-01-312012-05-29Ethicon Endo-Surgery, Inc.Motor-driven surgical cutting and fastening instrument with mechanical closure system
US8820603B2 (en)2006-01-312014-09-02Ethicon Endo-Surgery, Inc.Accessing data stored in a memory of a surgical instrument
US20120292367A1 (en)2006-01-312012-11-22Ethicon Endo-Surgery, Inc.Robotically-controlled end effector
US7845537B2 (en)2006-01-312010-12-07Ethicon Endo-Surgery, Inc.Surgical instrument having recording capabilities
US11224427B2 (en)2006-01-312022-01-18Cilag Gmbh InternationalSurgical stapling system including a console and retraction assembly
US20110024477A1 (en)2009-02-062011-02-03Hall Steven GDriven Surgical Stapler Improvements
US11278279B2 (en)2006-01-312022-03-22Cilag Gmbh InternationalSurgical instrument assembly
US7753904B2 (en)2006-01-312010-07-13Ethicon Endo-Surgery, Inc.Endoscopic surgical instrument with a handle that can articulate with respect to the shaft
US8708213B2 (en)2006-01-312014-04-29Ethicon Endo-Surgery, Inc.Surgical instrument having a feedback system
US20110295295A1 (en)2006-01-312011-12-01Ethicon Endo-Surgery, Inc.Robotically-controlled surgical instrument having recording capabilities
US11793518B2 (en)2006-01-312023-10-24Cilag Gmbh InternationalPowered surgical instruments with firing system lockout arrangements
US8992422B2 (en)2006-03-232015-03-31Ethicon Endo-Surgery, Inc.Robotically-controlled endoscopic accessory channel
US8322455B2 (en)2006-06-272012-12-04Ethicon Endo-Surgery, Inc.Manually driven surgical cutting and fastening instrument
US10568652B2 (en)2006-09-292020-02-25Ethicon LlcSurgical staples having attached drivers of different heights and stapling instruments for deploying the same
US11980366B2 (en)2006-10-032024-05-14Cilag Gmbh InternationalSurgical instrument
US11291441B2 (en)2007-01-102022-04-05Cilag Gmbh InternationalSurgical instrument with wireless communication between control unit and remote sensor
US8632535B2 (en)2007-01-102014-01-21Ethicon Endo-Surgery, Inc.Interlock and surgical instrument including same
US8684253B2 (en)2007-01-102014-04-01Ethicon Endo-Surgery, Inc.Surgical instrument with wireless communication between a control unit of a robotic system and remote sensor
US20080169333A1 (en)2007-01-112008-07-17Shelton Frederick ESurgical stapler end effector with tapered distal end
US11039836B2 (en)2007-01-112021-06-22Cilag Gmbh InternationalStaple cartridge for use with a surgical stapling instrument
US7673782B2 (en)2007-03-152010-03-09Ethicon Endo-Surgery, Inc.Surgical stapling instrument having a releasable buttress material
US8931682B2 (en)2007-06-042015-01-13Ethicon Endo-Surgery, Inc.Robotically-controlled shaft based rotary drive systems for surgical instruments
US11564682B2 (en)2007-06-042023-01-31Cilag Gmbh InternationalSurgical stapler device
US7753245B2 (en)2007-06-222010-07-13Ethicon Endo-Surgery, Inc.Surgical stapling instruments
US11849941B2 (en)2007-06-292023-12-26Cilag Gmbh InternationalStaple cartridge having staple cavities extending at a transverse angle relative to a longitudinal cartridge axis
US8573465B2 (en)2008-02-142013-11-05Ethicon Endo-Surgery, Inc.Robotically-controlled surgical end effector system with rotary actuated closure systems
US11986183B2 (en)2008-02-142024-05-21Cilag Gmbh InternationalSurgical cutting and fastening instrument comprising a plurality of sensors to measure an electrical parameter
US8636736B2 (en)2008-02-142014-01-28Ethicon Endo-Surgery, Inc.Motorized surgical cutting and fastening instrument
US9179912B2 (en)2008-02-142015-11-10Ethicon Endo-Surgery, Inc.Robotically-controlled motorized surgical cutting and fastening instrument
US7819298B2 (en)2008-02-142010-10-26Ethicon Endo-Surgery, Inc.Surgical stapling apparatus with control features operable with one hand
JP5410110B2 (en)2008-02-142014-02-05エシコン・エンド−サージェリィ・インコーポレイテッド Surgical cutting / fixing instrument with RF electrode
US8758391B2 (en)2008-02-142014-06-24Ethicon Endo-Surgery, Inc.Interchangeable tools for surgical instruments
US7866527B2 (en)2008-02-142011-01-11Ethicon Endo-Surgery, Inc.Surgical stapling apparatus with interlockable firing system
US9585657B2 (en)2008-02-152017-03-07Ethicon Endo-Surgery, LlcActuator for releasing a layer of material from a surgical end effector
US11648005B2 (en)2008-09-232023-05-16Cilag Gmbh InternationalRobotically-controlled motorized surgical instrument with an end effector
US8210411B2 (en)2008-09-232012-07-03Ethicon Endo-Surgery, Inc.Motor-driven surgical cutting instrument
US9005230B2 (en)2008-09-232015-04-14Ethicon Endo-Surgery, Inc.Motorized surgical instrument
US9386983B2 (en)2008-09-232016-07-12Ethicon Endo-Surgery, LlcRobotically-controlled motorized surgical instrument
US8608045B2 (en)2008-10-102013-12-17Ethicon Endo-Sugery, Inc.Powered surgical cutting and stapling apparatus with manually retractable firing system
US8517239B2 (en)2009-02-052013-08-27Ethicon Endo-Surgery, Inc.Surgical stapling instrument comprising a magnetic element driver
RU2525225C2 (en)2009-02-062014-08-10Этикон Эндо-Серджери, Инк.Improvement of drive surgical suturing instrument
US8220688B2 (en)2009-12-242012-07-17Ethicon Endo-Surgery, Inc.Motor-driven surgical cutting instrument with electric actuator directional control assembly
US8851354B2 (en)2009-12-242014-10-07Ethicon Endo-Surgery, Inc.Surgical cutting instrument that analyzes tissue thickness
US8783543B2 (en)2010-07-302014-07-22Ethicon Endo-Surgery, Inc.Tissue acquisition arrangements and methods for surgical stapling devices
US11925354B2 (en)2010-09-302024-03-12Cilag Gmbh InternationalStaple cartridge comprising staples positioned within a compressible portion thereof
US11812965B2 (en)2010-09-302023-11-14Cilag Gmbh InternationalLayer of material for a surgical end effector
US9351730B2 (en)2011-04-292016-05-31Ethicon Endo-Surgery, LlcTissue thickness compensator comprising channels
US12213666B2 (en)2010-09-302025-02-04Cilag Gmbh InternationalTissue thickness compensator comprising layers
US11298125B2 (en)2010-09-302022-04-12Cilag Gmbh InternationalTissue stapler having a thickness compensator
US9629814B2 (en)2010-09-302017-04-25Ethicon Endo-Surgery, LlcTissue thickness compensator configured to redistribute compressive forces
US10945731B2 (en)2010-09-302021-03-16Ethicon LlcTissue thickness compensator comprising controlled release and expansion
US9788834B2 (en)2010-09-302017-10-17Ethicon LlcLayer comprising deployable attachment members
US9386988B2 (en)2010-09-302016-07-12Ethicon End-Surgery, LLCRetainer assembly including a tissue thickness compensator
US9016542B2 (en)2010-09-302015-04-28Ethicon Endo-Surgery, Inc.Staple cartridge comprising compressible distortion resistant components
US8695866B2 (en)2010-10-012014-04-15Ethicon Endo-Surgery, Inc.Surgical instrument having a power control circuit
AU2012250197B2 (en)2011-04-292017-08-10Ethicon Endo-Surgery, Inc.Staple cartridge comprising staples positioned within a compressible portion thereof
US11207064B2 (en)2011-05-272021-12-28Cilag Gmbh InternationalAutomated end effector component reloading system for use with a robotic system
US9044230B2 (en)2012-02-132015-06-02Ethicon Endo-Surgery, Inc.Surgical cutting and fastening instrument with apparatus for determining cartridge and firing motion status
JP6224070B2 (en)2012-03-282017-11-01エシコン・エンド−サージェリィ・インコーポレイテッドEthicon Endo−Surgery,Inc. Retainer assembly including tissue thickness compensator
BR112014024098B1 (en)2012-03-282021-05-25Ethicon Endo-Surgery, Inc. staple cartridge
MX358135B (en)2012-03-282018-08-06Ethicon Endo Surgery IncTissue thickness compensator comprising a plurality of layers.
US9101358B2 (en)2012-06-152015-08-11Ethicon Endo-Surgery, Inc.Articulatable surgical instrument comprising a firing drive
US9282974B2 (en)2012-06-282016-03-15Ethicon Endo-Surgery, LlcEmpty clip cartridge lockout
US9289256B2 (en)2012-06-282016-03-22Ethicon Endo-Surgery, LlcSurgical end effectors having angled tissue-contacting surfaces
BR112014032776B1 (en)2012-06-282021-09-08Ethicon Endo-Surgery, Inc SURGICAL INSTRUMENT SYSTEM AND SURGICAL KIT FOR USE WITH A SURGICAL INSTRUMENT SYSTEM
US9408606B2 (en)2012-06-282016-08-09Ethicon Endo-Surgery, LlcRobotically powered surgical device with manually-actuatable reversing system
US11278284B2 (en)2012-06-282022-03-22Cilag Gmbh InternationalRotary drive arrangements for surgical instruments
US20140001231A1 (en)2012-06-282014-01-02Ethicon Endo-Surgery, Inc.Firing system lockout arrangements for surgical instruments
US12383267B2 (en)2012-06-282025-08-12Cilag Gmbh InternationalRobotically powered surgical device with manually-actuatable reversing system
JP6290201B2 (en)2012-06-282018-03-07エシコン・エンド−サージェリィ・インコーポレイテッドEthicon Endo−Surgery,Inc. Lockout for empty clip cartridge
RU2672520C2 (en)2013-03-012018-11-15Этикон Эндо-Серджери, Инк.Hingedly turnable surgical instruments with conducting ways for signal transfer
BR112015021082B1 (en)2013-03-012022-05-10Ethicon Endo-Surgery, Inc surgical instrument
US9629629B2 (en)2013-03-142017-04-25Ethicon Endo-Surgey, LLCControl systems for surgical instruments
US9808244B2 (en)2013-03-142017-11-07Ethicon LlcSensor arrangements for absolute positioning system for surgical instruments
BR112015026109B1 (en)2013-04-162022-02-22Ethicon Endo-Surgery, Inc surgical instrument
US9826976B2 (en)2013-04-162017-11-28Ethicon LlcMotor driven surgical instruments with lockable dual drive shafts
MX369362B (en)2013-08-232019-11-06Ethicon Endo Surgery LlcFiring member retraction devices for powered surgical instruments.
US9775609B2 (en)2013-08-232017-10-03Ethicon LlcTamper proof circuit for surgical instrument battery pack
US9962161B2 (en)2014-02-122018-05-08Ethicon LlcDeliverable surgical instrument
US12232723B2 (en)2014-03-262025-02-25Cilag Gmbh InternationalSystems and methods for controlling a segmented circuit
BR112016021943B1 (en)2014-03-262022-06-14Ethicon Endo-Surgery, Llc SURGICAL INSTRUMENT FOR USE BY AN OPERATOR IN A SURGICAL PROCEDURE
US10004497B2 (en)2014-03-262018-06-26Ethicon LlcInterface systems for use with surgical instruments
US10013049B2 (en)2014-03-262018-07-03Ethicon LlcPower management through sleep options of segmented circuit and wake up control
US20150272580A1 (en)2014-03-262015-10-01Ethicon Endo-Surgery, Inc.Verification of number of battery exchanges/procedure count
US20150297225A1 (en)2014-04-162015-10-22Ethicon Endo-Surgery, Inc.Fastener cartridges including extensions having different configurations
BR112016023825B1 (en)2014-04-162022-08-02Ethicon Endo-Surgery, Llc STAPLE CARTRIDGE FOR USE WITH A SURGICAL STAPLER AND STAPLE CARTRIDGE FOR USE WITH A SURGICAL INSTRUMENT
CN106456176B (en)2014-04-162019-06-28伊西康内外科有限责任公司 Fastener Cartridge Including Extensions With Different Configurations
CN106456159B (en)2014-04-162019-03-08伊西康内外科有限责任公司 Fastener Cartridge Assembly and Nail Retainer Cover Arrangement
US10327764B2 (en)2014-09-262019-06-25Ethicon LlcMethod for creating a flexible staple line
US10470768B2 (en)2014-04-162019-11-12Ethicon LlcFastener cartridge including a layer attached thereto
US11311294B2 (en)2014-09-052022-04-26Cilag Gmbh InternationalPowered medical device including measurement of closure state of jaws
BR112017004361B1 (en)2014-09-052023-04-11Ethicon Llc ELECTRONIC SYSTEM FOR A SURGICAL INSTRUMENT
US10135242B2 (en)2014-09-052018-11-20Ethicon LlcSmart cartridge wake up operation and data retention
US10105142B2 (en)2014-09-182018-10-23Ethicon LlcSurgical stapler with plurality of cutting elements
US11523821B2 (en)2014-09-262022-12-13Cilag Gmbh InternationalMethod for creating a flexible staple line
CN107427300B (en)2014-09-262020-12-04伊西康有限责任公司 Surgical suture buttresses and auxiliary materials
US10076325B2 (en)2014-10-132018-09-18Ethicon LlcSurgical stapling apparatus comprising a tissue stop
US9924944B2 (en)2014-10-162018-03-27Ethicon LlcStaple cartridge comprising an adjunct material
US10517594B2 (en)2014-10-292019-12-31Ethicon LlcCartridge assemblies for surgical staplers
US11141153B2 (en)2014-10-292021-10-12Cilag Gmbh InternationalStaple cartridges comprising driver arrangements
US9844376B2 (en)2014-11-062017-12-19Ethicon LlcStaple cartridge comprising a releasable adjunct material
US10736636B2 (en)2014-12-102020-08-11Ethicon LlcArticulatable surgical instrument system
US9844374B2 (en)2014-12-182017-12-19Ethicon LlcSurgical instrument systems comprising an articulatable end effector and means for adjusting the firing stroke of a firing member
US9844375B2 (en)2014-12-182017-12-19Ethicon LlcDrive arrangements for articulatable surgical instruments
US10085748B2 (en)2014-12-182018-10-02Ethicon LlcLocking arrangements for detachable shaft assemblies with articulatable surgical end effectors
US9987000B2 (en)2014-12-182018-06-05Ethicon LlcSurgical instrument assembly comprising a flexible articulation system
US9943309B2 (en)2014-12-182018-04-17Ethicon LlcSurgical instruments with articulatable end effectors and movable firing beam support arrangements
MX389118B (en)2014-12-182025-03-20Ethicon Llc SURGICAL INSTRUMENT WITH AN ANVIL THAT CAN BE SELECTIVELY MOVED ON A DISCRETE, NON-MOBILE AXIS RELATIVE TO A STAPLE CARTRIDGE.
EP3061442A1 (en)2015-02-272016-08-31Evonik Degussa GmbHComposition comprising rhamnolipid and siloxane
US11154301B2 (en)2015-02-272021-10-26Cilag Gmbh InternationalModular stapling assembly
US10617412B2 (en)2015-03-062020-04-14Ethicon LlcSystem for detecting the mis-insertion of a staple cartridge into a surgical stapler
US9993248B2 (en)2015-03-062018-06-12Ethicon Endo-Surgery, LlcSmart sensors with local signal processing
JP2020121162A (en)2015-03-062020-08-13エシコン エルエルシーEthicon LLCTime dependent evaluation of sensor data to determine stability element, creep element and viscoelastic element of measurement
US10687806B2 (en)2015-03-062020-06-23Ethicon LlcAdaptive tissue compression techniques to adjust closure rates for multiple tissue types
US10245033B2 (en)2015-03-062019-04-02Ethicon LlcSurgical instrument comprising a lockable battery housing
US9901342B2 (en)2015-03-062018-02-27Ethicon Endo-Surgery, LlcSignal and power communication system positioned on a rotatable shaft
US10441279B2 (en)2015-03-062019-10-15Ethicon LlcMultiple level thresholds to modify operation of powered surgical instruments
US10548504B2 (en)2015-03-062020-02-04Ethicon LlcOverlaid multi sensor radio frequency (RF) electrode system to measure tissue compression
WO2016145561A1 (en)2015-03-132016-09-22Evonik Specialty Chemicals (Shanghai) Co., Ltd.Peg free stable low viscosity oil-in-water emulsion and use thereof
US10433844B2 (en)2015-03-312019-10-08Ethicon LlcSurgical instrument with selectively disengageable threaded drive systems
US10835249B2 (en)2015-08-172020-11-17Ethicon LlcImplantable layers for a surgical instrument
US10238386B2 (en)2015-09-232019-03-26Ethicon LlcSurgical stapler having motor control based on an electrical parameter related to a motor current
US10105139B2 (en)2015-09-232018-10-23Ethicon LlcSurgical stapler having downstream current-based motor control
US10299878B2 (en)2015-09-252019-05-28Ethicon LlcImplantable adjunct systems for determining adjunct skew
US10980539B2 (en)2015-09-302021-04-20Ethicon LlcImplantable adjunct comprising bonded layers
US11890015B2 (en)2015-09-302024-02-06Cilag Gmbh InternationalCompressible adjunct with crossing spacer fibers
US10478188B2 (en)2015-09-302019-11-19Ethicon LlcImplantable layer comprising a constricted configuration
US10433846B2 (en)2015-09-302019-10-08Ethicon LlcCompressible adjunct with crossing spacer fibers
US10368865B2 (en)2015-12-302019-08-06Ethicon LlcMechanisms for compensating for drivetrain failure in powered surgical instruments
US10292704B2 (en)2015-12-302019-05-21Ethicon LlcMechanisms for compensating for battery pack failure in powered surgical instruments
US10265068B2 (en)2015-12-302019-04-23Ethicon LlcSurgical instruments with separable motors and motor control circuits
US11213293B2 (en)2016-02-092022-01-04Cilag Gmbh InternationalArticulatable surgical instruments with single articulation link arrangements
BR112018016098B1 (en)2016-02-092023-02-23Ethicon Llc SURGICAL INSTRUMENT
US11224426B2 (en)2016-02-122022-01-18Cilag Gmbh InternationalMechanisms for compensating for drivetrain failure in powered surgical instruments
US10448948B2 (en)2016-02-122019-10-22Ethicon LlcMechanisms for compensating for drivetrain failure in powered surgical instruments
US10357247B2 (en)2016-04-152019-07-23Ethicon LlcSurgical instrument with multiple program responses during a firing motion
US10335145B2 (en)2016-04-152019-07-02Ethicon LlcModular surgical instrument with configurable operating mode
US11607239B2 (en)2016-04-152023-03-21Cilag Gmbh InternationalSystems and methods for controlling a surgical stapling and cutting instrument
US10426467B2 (en)2016-04-152019-10-01Ethicon LlcSurgical instrument with detection sensors
US10828028B2 (en)2016-04-152020-11-10Ethicon LlcSurgical instrument with multiple program responses during a firing motion
US11179150B2 (en)2016-04-152021-11-23Cilag Gmbh InternationalSystems and methods for controlling a surgical stapling and cutting instrument
US10492783B2 (en)2016-04-152019-12-03Ethicon, LlcSurgical instrument with improved stop/start control during a firing motion
US10456137B2 (en)2016-04-152019-10-29Ethicon LlcStaple formation detection mechanisms
US11317917B2 (en)2016-04-182022-05-03Cilag Gmbh InternationalSurgical stapling system comprising a lockable firing assembly
US10363037B2 (en)2016-04-182019-07-30Ethicon LlcSurgical instrument system comprising a magnetic lockout
US20170296173A1 (en)2016-04-182017-10-19Ethicon Endo-Surgery, LlcMethod for operating a surgical instrument
EP3478655B1 (en)2016-06-292020-09-30Evonik Operations GmbHMethod for producing surfactants
CN109476949B (en)2016-07-192021-06-08赢创运营有限公司 Use of polyol esters for the production of porous plastic coatings
US10500000B2 (en)2016-08-162019-12-10Ethicon LlcSurgical tool with manual control of end effector jaws
CN109563021B (en)2016-08-182021-11-26赢创运营有限公司Cross-linked polyglycerol esters
JP2020501815A (en)2016-12-212020-01-23エシコン エルエルシーEthicon LLC Surgical stapling system
US11090048B2 (en)2016-12-212021-08-17Cilag Gmbh InternationalMethod for resetting a fuse of a surgical instrument shaft
MX2019007295A (en)2016-12-212019-10-15Ethicon LlcSurgical instrument system comprising an end effector lockout and a firing assembly lockout.
US10813638B2 (en)2016-12-212020-10-27Ethicon LlcSurgical end effectors with expandable tissue stop arrangements
JP7010956B2 (en)2016-12-212022-01-26エシコン エルエルシー How to staple tissue
US20180168615A1 (en)2016-12-212018-06-21Ethicon Endo-Surgery, LlcMethod of deforming staples from two different types of staple cartridges with the same surgical stapling instrument
US10898186B2 (en)2016-12-212021-01-26Ethicon LlcStaple forming pocket arrangements comprising primary sidewalls and pocket sidewalls
US10542982B2 (en)2016-12-212020-01-28Ethicon LlcShaft assembly comprising first and second articulation lockouts
US10485543B2 (en)2016-12-212019-11-26Ethicon LlcAnvil having a knife slot width
US10758229B2 (en)2016-12-212020-09-01Ethicon LlcSurgical instrument comprising improved jaw control
US10582928B2 (en)2016-12-212020-03-10Ethicon LlcArticulation lock arrangements for locking an end effector in an articulated position in response to actuation of a jaw closure system
US10695055B2 (en)2016-12-212020-06-30Ethicon LlcFiring assembly comprising a lockout
US10973516B2 (en)2016-12-212021-04-13Ethicon LlcSurgical end effectors and adaptable firing members therefor
US10980536B2 (en)2016-12-212021-04-20Ethicon LlcNo-cartridge and spent cartridge lockout arrangements for surgical staplers
JP7010957B2 (en)2016-12-212022-01-26エシコン エルエルシー Shaft assembly with lockout
US10568625B2 (en)2016-12-212020-02-25Ethicon LlcStaple cartridges and arrangements of staples and staple cavities therein
US11419606B2 (en)2016-12-212022-08-23Cilag Gmbh InternationalShaft assembly comprising a clutch configured to adapt the output of a rotary firing member to two different systems
JP6983893B2 (en)2016-12-212021-12-17エシコン エルエルシーEthicon LLC Lockout configuration for surgical end effectors and replaceable tool assemblies
CN110087565A (en)2016-12-212019-08-02爱惜康有限责任公司Surgical stapling system
US20180168625A1 (en)2016-12-212018-06-21Ethicon Endo-Surgery, LlcSurgical stapling instruments with smart staple cartridges
US11134942B2 (en)2016-12-212021-10-05Cilag Gmbh InternationalSurgical stapling instruments and staple-forming anvils
JP7271431B2 (en)2017-02-102023-05-11エボニック オペレーションズ ゲーエムベーハー Oral care composition containing at least one biosurfactant and fluoride
US11071554B2 (en)2017-06-202021-07-27Cilag Gmbh InternationalClosed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on magnitude of velocity error measurements
US11382638B2 (en)2017-06-202022-07-12Cilag Gmbh InternationalClosed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on measured time over a specified displacement distance
US11517325B2 (en)2017-06-202022-12-06Cilag Gmbh InternationalClosed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on measured displacement distance traveled over a specified time interval
US10307170B2 (en)2017-06-202019-06-04Ethicon LlcMethod for closed loop control of motor velocity of a surgical stapling and cutting instrument
US10624633B2 (en)2017-06-202020-04-21Ethicon LlcSystems and methods for controlling motor velocity of a surgical stapling and cutting instrument
US10881396B2 (en)2017-06-202021-01-05Ethicon LlcSurgical instrument with variable duration trigger arrangement
US10813639B2 (en)2017-06-202020-10-27Ethicon LlcClosed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on system conditions
US10881399B2 (en)2017-06-202021-01-05Ethicon LlcTechniques for adaptive control of motor velocity of a surgical stapling and cutting instrument
US11090046B2 (en)2017-06-202021-08-17Cilag Gmbh InternationalSystems and methods for controlling displacement member motion of a surgical stapling and cutting instrument
US11653914B2 (en)2017-06-202023-05-23Cilag Gmbh InternationalSystems and methods for controlling motor velocity of a surgical stapling and cutting instrument according to articulation angle of end effector
US10646220B2 (en)2017-06-202020-05-12Ethicon LlcSystems and methods for controlling displacement member velocity for a surgical instrument
US10888321B2 (en)2017-06-202021-01-12Ethicon LlcSystems and methods for controlling velocity of a displacement member of a surgical stapling and cutting instrument
USD879808S1 (en)2017-06-202020-03-31Ethicon LlcDisplay panel with graphical user interface
USD879809S1 (en)2017-06-202020-03-31Ethicon LlcDisplay panel with changeable graphical user interface
US10779820B2 (en)2017-06-202020-09-22Ethicon LlcSystems and methods for controlling motor speed according to user input for a surgical instrument
USD890784S1 (en)2017-06-202020-07-21Ethicon LlcDisplay panel with changeable graphical user interface
US10980537B2 (en)2017-06-202021-04-20Ethicon LlcClosed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on measured time over a specified number of shaft rotations
US11324503B2 (en)2017-06-272022-05-10Cilag Gmbh InternationalSurgical firing member arrangements
US11090049B2 (en)2017-06-272021-08-17Cilag Gmbh InternationalStaple forming pocket arrangements
US11266405B2 (en)2017-06-272022-03-08Cilag Gmbh InternationalSurgical anvil manufacturing methods
US10993716B2 (en)2017-06-272021-05-04Ethicon LlcSurgical anvil arrangements
US10856869B2 (en)2017-06-272020-12-08Ethicon LlcSurgical anvil arrangements
US10772629B2 (en)2017-06-272020-09-15Ethicon LlcSurgical anvil arrangements
US10758232B2 (en)2017-06-282020-09-01Ethicon LlcSurgical instrument with positive jaw opening features
EP3420947B1 (en)2017-06-282022-05-25Cilag GmbH InternationalSurgical instrument comprising selectively actuatable rotatable couplers
US11246592B2 (en)2017-06-282022-02-15Cilag Gmbh InternationalSurgical instrument comprising an articulation system lockable to a frame
US10903685B2 (en)2017-06-282021-01-26Ethicon LlcSurgical shaft assemblies with slip ring assemblies forming capacitive channels
USD906355S1 (en)2017-06-282020-12-29Ethicon LlcDisplay screen or portion thereof with a graphical user interface for a surgical instrument
US10765427B2 (en)2017-06-282020-09-08Ethicon LlcMethod for articulating a surgical instrument
US10716614B2 (en)2017-06-282020-07-21Ethicon LlcSurgical shaft assemblies with slip ring assemblies with increased contact pressure
US11259805B2 (en)2017-06-282022-03-01Cilag Gmbh InternationalSurgical instrument comprising firing member supports
US11564686B2 (en)2017-06-282023-01-31Cilag Gmbh InternationalSurgical shaft assemblies with flexible interfaces
US11484310B2 (en)2017-06-282022-11-01Cilag Gmbh InternationalSurgical instrument comprising a shaft including a closure tube profile
US11007022B2 (en)2017-06-292021-05-18Ethicon LlcClosed loop velocity control techniques based on sensed tissue parameters for robotic surgical instrument
US10932772B2 (en)2017-06-292021-03-02Ethicon LlcMethods for closed loop velocity control for robotic surgical instrument
US10898183B2 (en)2017-06-292021-01-26Ethicon LlcRobotic surgical instrument with closed loop feedback techniques for advancement of closure member during firing
US11944300B2 (en)2017-08-032024-04-02Cilag Gmbh InternationalMethod for operating a surgical system bailout
US11304695B2 (en)2017-08-032022-04-19Cilag Gmbh InternationalSurgical system shaft interconnection
US11974742B2 (en)2017-08-032024-05-07Cilag Gmbh InternationalSurgical system comprising an articulation bailout
US11471155B2 (en)2017-08-032022-10-18Cilag Gmbh InternationalSurgical system bailout
WO2019038125A1 (en)2017-08-242019-02-28Evonik Degussa Gmbh RHAMNOLIPID DERIVATIVES AS EMULSIFIERS AND DISPERSION TOOLS
JP7428637B2 (en)2017-08-302024-02-06エボニック オペレーションズ ゲーエムベーハー Use of polyol ethers to produce porous plastic coatings
JP7049868B2 (en)*2017-09-212022-04-07ライオン株式会社 Antiperspirant composition
WO2019058904A1 (en)*2017-09-212019-03-28ライオン株式会社Antiperspirant composition
US10765429B2 (en)2017-09-292020-09-08Ethicon LlcSystems and methods for providing alerts according to the operational state of a surgical instrument
US10743872B2 (en)2017-09-292020-08-18Ethicon LlcSystem and methods for controlling a display of a surgical instrument
USD907648S1 (en)2017-09-292021-01-12Ethicon LlcDisplay screen or portion thereof with animated graphical user interface
USD907647S1 (en)2017-09-292021-01-12Ethicon LlcDisplay screen or portion thereof with animated graphical user interface
US11399829B2 (en)2017-09-292022-08-02Cilag Gmbh InternationalSystems and methods of initiating a power shutdown mode for a surgical instrument
USD917500S1 (en)2017-09-292021-04-27Ethicon LlcDisplay screen or portion thereof with graphical user interface
US11134944B2 (en)2017-10-302021-10-05Cilag Gmbh InternationalSurgical stapler knife motion controls
US11090075B2 (en)2017-10-302021-08-17Cilag Gmbh InternationalArticulation features for surgical end effector
US10842490B2 (en)2017-10-312020-11-24Ethicon LlcCartridge body design with force reduction based on firing completion
US10779903B2 (en)2017-10-312020-09-22Ethicon LlcPositive shaft rotation lock activated by jaw closure
EP3710503B1 (en)2017-11-152022-01-05Evonik Operations GmbHFunctionalized polymers
US10743875B2 (en)2017-12-152020-08-18Ethicon LlcSurgical end effectors with jaw stiffener arrangements configured to permit monitoring of firing member
US11071543B2 (en)2017-12-152021-07-27Cilag Gmbh InternationalSurgical end effectors with clamping assemblies configured to increase jaw aperture ranges
US11033267B2 (en)2017-12-152021-06-15Ethicon LlcSystems and methods of controlling a clamping member firing rate of a surgical instrument
US10828033B2 (en)2017-12-152020-11-10Ethicon LlcHandheld electromechanical surgical instruments with improved motor control arrangements for positioning components of an adapter coupled thereto
US11006955B2 (en)2017-12-152021-05-18Ethicon LlcEnd effectors with positive jaw opening features for use with adapters for electromechanical surgical instruments
US11197670B2 (en)2017-12-152021-12-14Cilag Gmbh InternationalSurgical end effectors with pivotal jaws configured to touch at their respective distal ends when fully closed
US10779825B2 (en)2017-12-152020-09-22Ethicon LlcAdapters with end effector position sensing and control arrangements for use in connection with electromechanical surgical instruments
US10743874B2 (en)*2017-12-152020-08-18Ethicon LlcSealed adapters for use with electromechanical surgical instruments
US10779826B2 (en)2017-12-152020-09-22Ethicon LlcMethods of operating surgical end effectors
US10966718B2 (en)2017-12-152021-04-06Ethicon LlcDynamic clamping assemblies with improved wear characteristics for use in connection with electromechanical surgical instruments
US10869666B2 (en)2017-12-152020-12-22Ethicon LlcAdapters with control systems for controlling multiple motors of an electromechanical surgical instrument
US10687813B2 (en)2017-12-152020-06-23Ethicon LlcAdapters with firing stroke sensing arrangements for use in connection with electromechanical surgical instruments
US10835330B2 (en)2017-12-192020-11-17Ethicon LlcMethod for determining the position of a rotatable jaw of a surgical instrument attachment assembly
US10729509B2 (en)2017-12-192020-08-04Ethicon LlcSurgical instrument comprising closure and firing locking mechanism
US10716565B2 (en)2017-12-192020-07-21Ethicon LlcSurgical instruments with dual articulation drivers
US11045270B2 (en)2017-12-192021-06-29Cilag Gmbh InternationalRobotic attachment comprising exterior drive actuator
US11020112B2 (en)2017-12-192021-06-01Ethicon LlcSurgical tools configured for interchangeable use with different controller interfaces
USD910847S1 (en)2017-12-192021-02-16Ethicon LlcSurgical instrument assembly
US11076853B2 (en)2017-12-212021-08-03Cilag Gmbh InternationalSystems and methods of displaying a knife position during transection for a surgical instrument
US11129680B2 (en)2017-12-212021-09-28Cilag Gmbh InternationalSurgical instrument comprising a projector
US12336705B2 (en)2017-12-212025-06-24Cilag Gmbh InternationalContinuous use self-propelled stapling instrument
US11311290B2 (en)2017-12-212022-04-26Cilag Gmbh InternationalSurgical instrument comprising an end effector dampener
US11179151B2 (en)2017-12-212021-11-23Cilag Gmbh InternationalSurgical instrument comprising a display
US11291440B2 (en)2018-08-202022-04-05Cilag Gmbh InternationalMethod for operating a powered articulatable surgical instrument
US20200054321A1 (en)2018-08-202020-02-20Ethicon LlcSurgical instruments with progressive jaw closure arrangements
US11253256B2 (en)2018-08-202022-02-22Cilag Gmbh InternationalArticulatable motor powered surgical instruments with dedicated articulation motor arrangements
US11083458B2 (en)2018-08-202021-08-10Cilag Gmbh InternationalPowered surgical instruments with clutching arrangements to convert linear drive motions to rotary drive motions
USD914878S1 (en)2018-08-202021-03-30Ethicon LlcSurgical instrument anvil
US11039834B2 (en)2018-08-202021-06-22Cilag Gmbh InternationalSurgical stapler anvils with staple directing protrusions and tissue stability features
US11324501B2 (en)2018-08-202022-05-10Cilag Gmbh InternationalSurgical stapling devices with improved closure members
US11207065B2 (en)2018-08-202021-12-28Cilag Gmbh InternationalMethod for fabricating surgical stapler anvils
US10912559B2 (en)2018-08-202021-02-09Ethicon LlcReinforced deformable anvil tip for surgical stapler anvil
US10856870B2 (en)2018-08-202020-12-08Ethicon LlcSwitching arrangements for motor powered articulatable surgical instruments
US11045192B2 (en)2018-08-202021-06-29Cilag Gmbh InternationalFabricating techniques for surgical stapler anvils
US10779821B2 (en)2018-08-202020-09-22Ethicon LlcSurgical stapler anvils with tissue stop features configured to avoid tissue pinch
US10842492B2 (en)2018-08-202020-11-24Ethicon LlcPowered articulatable surgical instruments with clutching and locking arrangements for linking an articulation drive system to a firing drive system
US11147551B2 (en)2019-03-252021-10-19Cilag Gmbh InternationalFiring drive arrangements for surgical systems
US11172929B2 (en)2019-03-252021-11-16Cilag Gmbh InternationalArticulation drive arrangements for surgical systems
US11696761B2 (en)2019-03-252023-07-11Cilag Gmbh InternationalFiring drive arrangements for surgical systems
US11147553B2 (en)2019-03-252021-10-19Cilag Gmbh InternationalFiring drive arrangements for surgical systems
US11432816B2 (en)2019-04-302022-09-06Cilag Gmbh InternationalArticulation pin for a surgical instrument
US11471157B2 (en)2019-04-302022-10-18Cilag Gmbh InternationalArticulation control mapping for a surgical instrument
US11426251B2 (en)2019-04-302022-08-30Cilag Gmbh InternationalArticulation directional lights on a surgical instrument
US11253254B2 (en)2019-04-302022-02-22Cilag Gmbh InternationalShaft rotation actuator on a surgical instrument
US11903581B2 (en)2019-04-302024-02-20Cilag Gmbh InternationalMethods for stapling tissue using a surgical instrument
US11452528B2 (en)2019-04-302022-09-27Cilag Gmbh InternationalArticulation actuators for a surgical instrument
US11648009B2 (en)2019-04-302023-05-16Cilag Gmbh InternationalRotatable jaw tip for a surgical instrument
US11478241B2 (en)2019-06-282022-10-25Cilag Gmbh InternationalStaple cartridge including projections
US11464601B2 (en)2019-06-282022-10-11Cilag Gmbh InternationalSurgical instrument comprising an RFID system for tracking a movable component
US11771419B2 (en)2019-06-282023-10-03Cilag Gmbh InternationalPackaging for a replaceable component of a surgical stapling system
US11497492B2 (en)2019-06-282022-11-15Cilag Gmbh InternationalSurgical instrument including an articulation lock
US11553971B2 (en)2019-06-282023-01-17Cilag Gmbh InternationalSurgical RFID assemblies for display and communication
US11298132B2 (en)2019-06-282022-04-12Cilag GmbH InlernationalStaple cartridge including a honeycomb extension
US11399837B2 (en)2019-06-282022-08-02Cilag Gmbh InternationalMechanisms for motor control adjustments of a motorized surgical instrument
US11523822B2 (en)2019-06-282022-12-13Cilag Gmbh InternationalBattery pack including a circuit interrupter
US11219455B2 (en)2019-06-282022-01-11Cilag Gmbh InternationalSurgical instrument including a lockout key
US12004740B2 (en)2019-06-282024-06-11Cilag Gmbh InternationalSurgical stapling system having an information decryption protocol
US11376098B2 (en)2019-06-282022-07-05Cilag Gmbh InternationalSurgical instrument system comprising an RFID system
US11627959B2 (en)2019-06-282023-04-18Cilag Gmbh InternationalSurgical instruments including manual and powered system lockouts
US11241235B2 (en)2019-06-282022-02-08Cilag Gmbh InternationalMethod of using multiple RFID chips with a surgical assembly
US11426167B2 (en)2019-06-282022-08-30Cilag Gmbh InternationalMechanisms for proper anvil attachment surgical stapling head assembly
US11224497B2 (en)2019-06-282022-01-18Cilag Gmbh InternationalSurgical systems with multiple RFID tags
US11291451B2 (en)2019-06-282022-04-05Cilag Gmbh InternationalSurgical instrument with battery compatibility verification functionality
US11051807B2 (en)2019-06-282021-07-06Cilag Gmbh InternationalPackaging assembly including a particulate trap
US11298127B2 (en)2019-06-282022-04-12Cilag GmbH InterationalSurgical stapling system having a lockout mechanism for an incompatible cartridge
US11660163B2 (en)2019-06-282023-05-30Cilag Gmbh InternationalSurgical system with RFID tags for updating motor assembly parameters
US11246678B2 (en)2019-06-282022-02-15Cilag Gmbh InternationalSurgical stapling system having a frangible RFID tag
US11638587B2 (en)2019-06-282023-05-02Cilag Gmbh InternationalRFID identification systems for surgical instruments
US11259803B2 (en)2019-06-282022-03-01Cilag Gmbh InternationalSurgical stapling system having an information encryption protocol
US11684434B2 (en)2019-06-282023-06-27Cilag Gmbh InternationalSurgical RFID assemblies for instrument operational setting control
US11607219B2 (en)2019-12-192023-03-21Cilag Gmbh InternationalStaple cartridge comprising a detachable tissue cutting knife
US11701111B2 (en)2019-12-192023-07-18Cilag Gmbh InternationalMethod for operating a surgical stapling instrument
US11504122B2 (en)2019-12-192022-11-22Cilag Gmbh InternationalSurgical instrument comprising a nested firing member
US11464512B2 (en)2019-12-192022-10-11Cilag Gmbh InternationalStaple cartridge comprising a curved deck surface
US11529139B2 (en)2019-12-192022-12-20Cilag Gmbh InternationalMotor driven surgical instrument
US11304696B2 (en)2019-12-192022-04-19Cilag Gmbh InternationalSurgical instrument comprising a powered articulation system
US12035913B2 (en)2019-12-192024-07-16Cilag Gmbh InternationalStaple cartridge comprising a deployable knife
US11234698B2 (en)2019-12-192022-02-01Cilag Gmbh InternationalStapling system comprising a clamp lockout and a firing lockout
US11529137B2 (en)2019-12-192022-12-20Cilag Gmbh InternationalStaple cartridge comprising driver retention members
US11559304B2 (en)2019-12-192023-01-24Cilag Gmbh InternationalSurgical instrument comprising a rapid closure mechanism
US11844520B2 (en)2019-12-192023-12-19Cilag Gmbh InternationalStaple cartridge comprising driver retention members
US11446029B2 (en)2019-12-192022-09-20Cilag Gmbh InternationalStaple cartridge comprising projections extending from a curved deck surface
US11576672B2 (en)2019-12-192023-02-14Cilag Gmbh InternationalSurgical instrument comprising a closure system including a closure member and an opening member driven by a drive screw
US11911032B2 (en)2019-12-192024-02-27Cilag Gmbh InternationalStaple cartridge comprising a seating cam
US11931033B2 (en)2019-12-192024-03-19Cilag Gmbh InternationalStaple cartridge comprising a latch lockout
US11291447B2 (en)2019-12-192022-04-05Cilag Gmbh InternationalStapling instrument comprising independent jaw closing and staple firing systems
US11905492B2 (en)*2020-02-212024-02-20Illinois Tool Works Inc.Odor removing composition comprising zinc ricinoleate and fluorosurfactant and methods of making thereof
FR3108034B1 (en)2020-03-112022-09-09Hyteck Deodorant composition
USD975851S1 (en)2020-06-022023-01-17Cilag Gmbh InternationalStaple cartridge
USD974560S1 (en)2020-06-022023-01-03Cilag Gmbh InternationalStaple cartridge
USD976401S1 (en)2020-06-022023-01-24Cilag Gmbh InternationalStaple cartridge
USD975278S1 (en)2020-06-022023-01-10Cilag Gmbh InternationalStaple cartridge
USD967421S1 (en)2020-06-022022-10-18Cilag Gmbh InternationalStaple cartridge
USD966512S1 (en)2020-06-022022-10-11Cilag Gmbh InternationalStaple cartridge
USD975850S1 (en)2020-06-022023-01-17Cilag Gmbh InternationalStaple cartridge
US11871925B2 (en)2020-07-282024-01-16Cilag Gmbh InternationalSurgical instruments with dual spherical articulation joint arrangements
US11452526B2 (en)2020-10-292022-09-27Cilag Gmbh InternationalSurgical instrument comprising a staged voltage regulation start-up system
US11517390B2 (en)2020-10-292022-12-06Cilag Gmbh InternationalSurgical instrument comprising a limited travel switch
US11717289B2 (en)2020-10-292023-08-08Cilag Gmbh InternationalSurgical instrument comprising an indicator which indicates that an articulation drive is actuatable
US11896217B2 (en)2020-10-292024-02-13Cilag Gmbh InternationalSurgical instrument comprising an articulation lock
US11534259B2 (en)2020-10-292022-12-27Cilag Gmbh InternationalSurgical instrument comprising an articulation indicator
US11844518B2 (en)2020-10-292023-12-19Cilag Gmbh InternationalMethod for operating a surgical instrument
US11617577B2 (en)2020-10-292023-04-04Cilag Gmbh InternationalSurgical instrument comprising a sensor configured to sense whether an articulation drive of the surgical instrument is actuatable
USD1013170S1 (en)2020-10-292024-01-30Cilag Gmbh InternationalSurgical instrument assembly
US12053175B2 (en)2020-10-292024-08-06Cilag Gmbh InternationalSurgical instrument comprising a stowed closure actuator stop
USD980425S1 (en)2020-10-292023-03-07Cilag Gmbh InternationalSurgical instrument assembly
US11779330B2 (en)2020-10-292023-10-10Cilag Gmbh InternationalSurgical instrument comprising a jaw alignment system
US11931025B2 (en)2020-10-292024-03-19Cilag Gmbh InternationalSurgical instrument comprising a releasable closure drive lock
US11944296B2 (en)2020-12-022024-04-02Cilag Gmbh InternationalPowered surgical instruments with external connectors
US11653915B2 (en)2020-12-022023-05-23Cilag Gmbh InternationalSurgical instruments with sled location detection and adjustment features
US11678882B2 (en)2020-12-022023-06-20Cilag Gmbh InternationalSurgical instruments with interactive features to remedy incidental sled movements
US11849943B2 (en)2020-12-022023-12-26Cilag Gmbh InternationalSurgical instrument with cartridge release mechanisms
US11627960B2 (en)2020-12-022023-04-18Cilag Gmbh InternationalPowered surgical instruments with smart reload with separately attachable exteriorly mounted wiring connections
US11653920B2 (en)2020-12-022023-05-23Cilag Gmbh InternationalPowered surgical instruments with communication interfaces through sterile barrier
US11890010B2 (en)2020-12-022024-02-06Cllag GmbH InternationalDual-sided reinforced reload for surgical instruments
US11737751B2 (en)2020-12-022023-08-29Cilag Gmbh InternationalDevices and methods of managing energy dissipated within sterile barriers of surgical instrument housings
US11744581B2 (en)2020-12-022023-09-05Cilag Gmbh InternationalPowered surgical instruments with multi-phase tissue treatment
US12324580B2 (en)2021-02-262025-06-10Cilag Gmbh InternationalMethod of powering and communicating with a staple cartridge
US12108951B2 (en)2021-02-262024-10-08Cilag Gmbh InternationalStaple cartridge comprising a sensing array and a temperature control system
US11793514B2 (en)2021-02-262023-10-24Cilag Gmbh InternationalStaple cartridge comprising sensor array which may be embedded in cartridge body
US11980362B2 (en)2021-02-262024-05-14Cilag Gmbh InternationalSurgical instrument system comprising a power transfer coil
US11723657B2 (en)2021-02-262023-08-15Cilag Gmbh InternationalAdjustable communication based on available bandwidth and power capacity
US11812964B2 (en)2021-02-262023-11-14Cilag Gmbh InternationalStaple cartridge comprising a power management circuit
US11744583B2 (en)2021-02-262023-09-05Cilag Gmbh InternationalDistal communication array to tune frequency of RF systems
US11751869B2 (en)2021-02-262023-09-12Cilag Gmbh InternationalMonitoring of multiple sensors over time to detect moving characteristics of tissue
US11925349B2 (en)2021-02-262024-03-12Cilag Gmbh InternationalAdjustment to transfer parameters to improve available power
US11730473B2 (en)2021-02-262023-08-22Cilag Gmbh InternationalMonitoring of manufacturing life-cycle
US11950777B2 (en)2021-02-262024-04-09Cilag Gmbh InternationalStaple cartridge comprising an information access control system
US11696757B2 (en)2021-02-262023-07-11Cilag Gmbh InternationalMonitoring of internal systems to detect and track cartridge motion status
US11701113B2 (en)2021-02-262023-07-18Cilag Gmbh InternationalStapling instrument comprising a separate power antenna and a data transfer antenna
US11950779B2 (en)2021-02-262024-04-09Cilag Gmbh InternationalMethod of powering and communicating with a staple cartridge
US11749877B2 (en)2021-02-262023-09-05Cilag Gmbh InternationalStapling instrument comprising a signal antenna
US11723658B2 (en)2021-03-222023-08-15Cilag Gmbh InternationalStaple cartridge comprising a firing lockout
US11806011B2 (en)2021-03-222023-11-07Cilag Gmbh InternationalStapling instrument comprising tissue compression systems
US11717291B2 (en)2021-03-222023-08-08Cilag Gmbh InternationalStaple cartridge comprising staples configured to apply different tissue compression
US11826042B2 (en)2021-03-222023-11-28Cilag Gmbh InternationalSurgical instrument comprising a firing drive including a selectable leverage mechanism
US11759202B2 (en)2021-03-222023-09-19Cilag Gmbh InternationalStaple cartridge comprising an implantable layer
US11826012B2 (en)2021-03-222023-11-28Cilag Gmbh InternationalStapling instrument comprising a pulsed motor-driven firing rack
US11737749B2 (en)2021-03-222023-08-29Cilag Gmbh InternationalSurgical stapling instrument comprising a retraction system
US11857183B2 (en)2021-03-242024-01-02Cilag Gmbh InternationalStapling assembly components having metal substrates and plastic bodies
US11744603B2 (en)2021-03-242023-09-05Cilag Gmbh InternationalMulti-axis pivot joints for surgical instruments and methods for manufacturing same
US11786239B2 (en)2021-03-242023-10-17Cilag Gmbh InternationalSurgical instrument articulation joint arrangements comprising multiple moving linkage features
US11849945B2 (en)2021-03-242023-12-26Cilag Gmbh InternationalRotary-driven surgical stapling assembly comprising eccentrically driven firing member
US11896219B2 (en)2021-03-242024-02-13Cilag Gmbh InternationalMating features between drivers and underside of a cartridge deck
US11849944B2 (en)2021-03-242023-12-26Cilag Gmbh InternationalDrivers for fastener cartridge assemblies having rotary drive screws
US11832816B2 (en)2021-03-242023-12-05Cilag Gmbh InternationalSurgical stapling assembly comprising nonplanar staples and planar staples
US11903582B2 (en)2021-03-242024-02-20Cilag Gmbh InternationalLeveraging surfaces for cartridge installation
US11786243B2 (en)2021-03-242023-10-17Cilag Gmbh InternationalFiring members having flexible portions for adapting to a load during a surgical firing stroke
US11896218B2 (en)2021-03-242024-02-13Cilag Gmbh InternationalMethod of using a powered stapling device
US12102323B2 (en)2021-03-242024-10-01Cilag Gmbh InternationalRotary-driven surgical stapling assembly comprising a floatable component
US11944336B2 (en)2021-03-242024-04-02Cilag Gmbh InternationalJoint arrangements for multi-planar alignment and support of operational drive shafts in articulatable surgical instruments
US11793516B2 (en)2021-03-242023-10-24Cilag Gmbh InternationalSurgical staple cartridge comprising longitudinal support beam
US11826047B2 (en)2021-05-282023-11-28Cilag Gmbh InternationalStapling instrument comprising jaw mounts
US11957337B2 (en)2021-10-182024-04-16Cilag Gmbh InternationalSurgical stapling assembly with offset ramped drive surfaces
US11980363B2 (en)2021-10-182024-05-14Cilag Gmbh InternationalRow-to-row staple array variations
US11877745B2 (en)2021-10-182024-01-23Cilag Gmbh InternationalSurgical stapling assembly having longitudinally-repeating staple leg clusters
US12239317B2 (en)2021-10-182025-03-04Cilag Gmbh InternationalAnvil comprising an arrangement of forming pockets proximal to tissue stop
US11937816B2 (en)2021-10-282024-03-26Cilag Gmbh InternationalElectrical lead arrangements for surgical instruments
US12089841B2 (en)2021-10-282024-09-17Cilag CmbH InternationalStaple cartridge identification systems
US12432790B2 (en)2021-10-282025-09-30Cilag Gmbh InternationalMethod and device for transmitting UART communications over a security short range wireless communication

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US2854382A (en)1957-06-251958-09-30Procter & GambleZirconyl hydroxy chloride antiperspirant compositions
US3792068A (en)1971-04-021974-02-12Procter & GambleDry powder aerosol antiperspirant composition incorporating dry powder antiperspirant active complex and process for its preparation
DE3041073C2 (en)*1980-10-311986-01-02Dynamit Nobel Ag, 5210 Troisdorf Wool wax substitutes
IT1224421B (en)1987-12-291990-10-04Lamberti Flli Spa MODIFIED GALATTOMANNANS AND REALIVE PREPARATION PROCEDURE
DE19922229A1 (en)*1999-05-142000-11-16Cognis Deutschland Gmbh Cosmetic and / or pharmaceutical preparations
GB0304508D0 (en)2003-02-272003-04-02Unilever PlcAntiperspirant actives and compositions
DE10361202A1 (en)2003-12-242005-07-28Beiersdorf Ag Cosmetic emulsion
EP2243517A1 (en)2009-04-202010-10-27Dr. Straetmans GmbHCosmetic or dermatological preparation
BR112013019103B1 (en)*2011-02-032018-02-14Akzo Nobel Chemicals International B.V. FORMULATION FOR PERSONAL CARE, METHOD FOR MANUFACTURING FORMULATION FOR PERSONAL CARE AND USE OF A MODIFIED STARCH WITH A SILICONATE AND A COSMETICALLY ACCEPTABLE VEHICLE
DE102011089340A1 (en)*2011-12-212013-06-27Henkel Ag & Co. Kgaa PEG-free antiperspirant oil-in-water emulsions with improved feel
DE102012215707A1 (en)*2012-09-052014-03-06Evonik Industries Ag Polyglycerol ester with particular oligomer distribution of polyglycerol
DE102014203868A1 (en)*2014-03-042015-09-10Evonik Degussa Gmbh Polyglycerol ester with particular oligomer distribution of polyglycerol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None*

Also Published As

Publication numberPublication date
CN107028795A (en)2017-08-11
CN107028795B (en)2021-09-28
US20170202770A1 (en)2017-07-20
BR102017000660B1 (en)2021-11-09
EP3192491A1 (en)2017-07-19
BR102017000660A2 (en)2017-07-25

Similar Documents

PublicationPublication DateTitle
EP3192491B1 (en)Composition comprising polyglycerol esters and hydroxy-alkyl modified guar
EP3113846B1 (en)Polyglycerol esters featuring a particular oligomer distribution in the polyglycerol
DE69403082T2 (en) AQUEOUS ALCOHOLIC COSMETIC MICROEMULSIONS
EP2705832B1 (en)Polyglycerol esters with special oligomer distribution of polyglycerol
EP2782645B1 (en)Use of isosorbide caprylates/caprates in deodorants and antiperspirants
EP3500550A1 (en)Cross-linked polyglycerol esters
EP2275078B1 (en)Cosmetic and dermatological compositions comprising (2-hydroxyethyl)urea
EP2739137B1 (en)Use of isosorbide monoesters as thickeners
EP1753513B1 (en)Cosmetic microemulsion-based formulation containing mandelic acid
WO2014060150A1 (en)Cosmetic or dermatological preparation for prophylaxis and/or treatment of atopic dermatitis
WO2015024567A1 (en)Antiperspirants with reduced itching effect
EP1092415A2 (en)Cosmetic and dermatologic photoprotective O/W-macroemulsions or O/W-microemulsions containing dihydroxyacetone
EP2033617A2 (en)Cosmetic care cream comprising a protein
DE602005001478T2 (en) Oil-in-water emulsified composition
EP1071466A1 (en)Glycolipid creams
EP2603194B1 (en)Stabilized w/o emulsions
WO2013182667A2 (en)Thickened antiperspirant roll-ons having an improved residue behavior
EP2086497B1 (en)Cosmetic or dermatological formulation with mandelic acid and auxiliaries
WO1996032923A2 (en)Anti-transpirants
EP2654698A2 (en)Low-viscosity w/o emulsions having a content of one or more glucosyl glycerides and one or more electrolytes
DE102016210037A1 (en) &#34;Highly effective antiperspirants with improved skin tolerance&#34;
DE202010011395U1 (en) Stabilized W / O emulsions
DE4421208A1 (en) Cosmetic and / or pharmaceutical O / W emulsions
DE102011077042A1 (en) Hair cosmetic preparations comprising polyglyceryl-10-stearate
JP2022110911A (en) external composition

Legal Events

DateCodeTitleDescription
PUAIPublic reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text:ORIGINAL CODE: 0009012

STAAInformation on the status of an ep patent application or granted ep patent

Free format text:STATUS: THE APPLICATION HAS BEEN PUBLISHED

AKDesignated contracting states

Kind code of ref document:A1

Designated state(s):AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AXRequest for extension of the european patent

Extension state:BA ME

STAAInformation on the status of an ep patent application or granted ep patent

Free format text:STATUS: REQUEST FOR EXAMINATION WAS MADE

17PRequest for examination filed

Effective date:20180111

RBVDesignated contracting states (corrected)

Designated state(s):AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

GRAPDespatch of communication of intention to grant a patent

Free format text:ORIGINAL CODE: EPIDOSNIGR1

STAAInformation on the status of an ep patent application or granted ep patent

Free format text:STATUS: GRANT OF PATENT IS INTENDED

INTGIntention to grant announced

Effective date:20190613

GRAJInformation related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text:ORIGINAL CODE: EPIDOSDIGR1

STAAInformation on the status of an ep patent application or granted ep patent

Free format text:STATUS: REQUEST FOR EXAMINATION WAS MADE

GRAPDespatch of communication of intention to grant a patent

Free format text:ORIGINAL CODE: EPIDOSNIGR1

STAAInformation on the status of an ep patent application or granted ep patent

Free format text:STATUS: GRANT OF PATENT IS INTENDED

INTCIntention to grant announced (deleted)
INTGIntention to grant announced

Effective date:20190917

GRASGrant fee paid

Free format text:ORIGINAL CODE: EPIDOSNIGR3

GRAA(expected) grant

Free format text:ORIGINAL CODE: 0009210

STAAInformation on the status of an ep patent application or granted ep patent

Free format text:STATUS: THE PATENT HAS BEEN GRANTED

RAP1Party data changed (applicant data changed or rights of an application transferred)

Owner name:EVONIK OPERATIONS GMBH

AKDesignated contracting states

Kind code of ref document:B1

Designated state(s):AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REGReference to a national code

Ref country code:GB

Ref legal event code:FG4D

Free format text:NOT ENGLISH

REGReference to a national code

Ref country code:CH

Ref legal event code:EP

REGReference to a national code

Ref country code:DE

Ref legal event code:R096

Ref document number:502016008297

Country of ref document:DE

REGReference to a national code

Ref country code:IE

Ref legal event code:FG4D

Free format text:LANGUAGE OF EP DOCUMENT: GERMAN

REGReference to a national code

Ref country code:AT

Ref legal event code:REF

Ref document number:1221796

Country of ref document:AT

Kind code of ref document:T

Effective date:20200215

REGReference to a national code

Ref country code:NL

Ref legal event code:MP

Effective date:20200108

REGReference to a national code

Ref country code:LT

Ref legal event code:MG4D

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:LT

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

Ref country code:NO

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200408

Ref country code:NL

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

Ref country code:FI

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

Ref country code:RS

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

Ref country code:PT

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200531

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:IS

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200508

Ref country code:GR

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200409

Ref country code:HR

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

Ref country code:LV

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

Ref country code:SE

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

Ref country code:BG

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200408

REGReference to a national code

Ref country code:CH

Ref legal event code:PL

REGReference to a national code

Ref country code:DE

Ref legal event code:R097

Ref document number:502016008297

Country of ref document:DE

REGReference to a national code

Ref country code:BE

Ref legal event code:MM

Effective date:20200131

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:DK

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

Ref country code:EE

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

Ref country code:SM

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

Ref country code:ES

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

Ref country code:RO

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

Ref country code:CZ

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

Ref country code:LU

Free format text:LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date:20200115

Ref country code:MC

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

Ref country code:SK

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

PLBENo opposition filed within time limit

Free format text:ORIGINAL CODE: 0009261

STAAInformation on the status of an ep patent application or granted ep patent

Free format text:STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:BE

Free format text:LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date:20200131

Ref country code:LI

Free format text:LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date:20200131

Ref country code:CH

Free format text:LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date:20200131

26NNo opposition filed

Effective date:20201009

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:IT

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

Ref country code:IE

Free format text:LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date:20200115

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:SI

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

Ref country code:PL

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

GBPCGb: european patent ceased through non-payment of renewal fee

Effective date:20200408

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:GB

Free format text:LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date:20200408

REGReference to a national code

Ref country code:AT

Ref legal event code:MM01

Ref document number:1221796

Country of ref document:AT

Kind code of ref document:T

Effective date:20210115

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:AT

Free format text:LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date:20210115

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:TR

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

Ref country code:MT

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

Ref country code:CY

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:MK

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

Ref country code:AL

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20200108

P01Opt-out of the competence of the unified patent court (upc) registered

Effective date:20230524

PGFPAnnual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code:DE

Payment date:20250121

Year of fee payment:10

PGFPAnnual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code:FR

Payment date:20250127

Year of fee payment:10


[8]ページ先頭

©2009-2025 Movatter.jp